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1. INTRODUCTION 
1.1 INTRODUCTION TO ANALYTICAL CHEMISTRY (Kellner et al., 2004)                                                      
Analytical chemistry is a metrological discipline that develops, optimizes and 
applied measurement processes intended to derive quality (bio) chemical information of 
global and partial type from natural and artificial objects or systems in order to solve 
analytical problems derived from information needs. 
1.1.1 Aims and Objectives 
 Thus, Analytical chemistry has two main aims are Qualitative (intrinsic) and 
Quantitative (Extrinsic). The Qualitative aim is the achievement of metrological quality, 
i.e. ensuring full consistency between the analytical results delivered and the actual value 
of the measured parameters; in metrological terms, this translates into producing high 
traceable results subject to very little uncertainty. The Quantitative aim is solving the 
analytical problems derived from the (bio) chemical information needs posed by a variety 
of “clients”. Example:- Industry and research centers. 
 The principal objective of analytical chemistry is to obtain as much (bio) chemical 
information and of as high a quality as possible from objects and systems by using as 
little material time, and human resources as possible and with minimal costs and risks. 
1.1.2 Two Sides of Analytical Chemistry 
The multitude of definitions of analytical chemistry issued to date coverage on 
two key features, namely its basic and applied natures, which is consistent with the two 
essential aims. 
 The basic side of analytical chemistry encompasses a variety of research and 
development activities aimed at expanding and improving its foundations, such activities 
include the development of new analytical tools and methods for the preparation of 
reference materials of a high metrological quality, and the establishment of new 
calibration procedures and chemometric approaches. 
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 The applied side is directly concerned with solving the analytical problems 
derived from (bio) chemical information needs in a variety of economic and social areas 
including industry, the environment, food science, pharmaceutical analysis and clinical 
analysis. The results obtained by analyzing such a variety of samples are used to make 
social and economic decisions within the frame work of the analytical problem 
concerned. 
1.2 IMPORTANCE OF ANALYSIS (Kellner et al., 2004) 
Newer analytical methods are developed for the drugs or drug combinations due 
to the patient must receive the good quality of drugs, the drug or drug combinations may 
not be official in any pharmacopoeia, a literature search may not reveal an analytical 
procedure for the drug or it combinations, analytical methods may not be available for the 
drug combinations due to interference caused by excipients and analytical methods for 
the quantification of drug or drug combinations from biological fluids may not be 
available. 
The  development of newer analytical methods are very importance in many of the 
fields like research institutions, quality control department in industries, approved testing 
laboratories, biopharmaceutical and bio equivalence study and clinical pharmacokinetic 
studies. 
1.3 ANALYTICAL ERRORS (Kellner et al., 2004) 
 Analytical information can be classified in to three major groups according to its 
nearness to the true value. Further classification allows one to establish the so-called 
“Chemical metrological hierarchy” 
 Analytical errors can be defined as alterations of the analytical information 
delivered, i.e. as differences between the true values or held as true and the parameters on 
the other levels of the metrological hierarchy, and also as differences between results. An 
analytical error can arise both from an analytical result and analytical process. It can be 
expressed in absolute or relative terms. There are three main types of analytical errors are 
random error, systemic error and gross error. 
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Types of Analytical Errors 
Differences between types 
of errors 
Types of Errors 
Random Systematic Gross 
Source Indeterminate Determinate (well defined) 
References for definition 
Means of a set 
(x ̄, ’) 
True value (xˆ) 
value held as true (xˆ) 
 
Sign 
Unpredictable   
(+) and (-) 
Unique                                               
(+) or ( -) 
Relative Magnitude (in 
general terms) 
Small Small Large 
Analytical properties 
involved 
Precision 
Accuracy 
Uncertainty (traceability) 
 
1.4 QUALITY AND THE ANALYTICAL PROBLEM 
 The general approach to quality encompasses both the basic and the practical side 
and their mutual complementary relationships. Analytical chemical quality has two 
additional components namely: (i) Metrological features, which include capital 
(accuracy, traceability, uncertainty) and basic analytical properties (precision, sensitivity, 
selectivity); and (ii) the analytical problem- solving process, which is related to capital 
and basic properties, and also to productivity- related properties (expeditiousness, cost- 
effectiveness, personnel-related factors). The basic and applied sides of quality in general 
and the analytical problem in particular are mutually related. 
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 Properly solving analytical problems in order to ensure client satisfaction is thus 
an essential ingredient of analytical quality. At present, analytical quality is frequently 
identified almost soley with the metrological side. It is widely accepted that “no quality 
is to be expected unless the objectives are properly defined”; in fact, the analytical 
problem provides analytical chemists with such objectives. Also, “quality is the concern 
of us all rather than a few”. It is therefore essential to have analytical laboratories 
systematically plan and solve analytical problems if integral analytical quality is to be 
achieved; this entails breaking some traditional barriers of analytical chemistry. 
Five General Steps Involving in Planning and Solving Analytical Problems 
1.5 ANALYSIS OF DRUGS IN BULK AND DOSAGE FORM 
Bulk drugs are obtained by chemical synthesis, biosynthesis isolation from plants 
or animals or biotechnological sources. Bulk drugs are manufactured in to dosage forms 
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with the help of additives prior to their use in patients. The purity and the suitability of 
drugs to be converted into dosage forms are assayed by analytical methods. The 
evaluation of dosage forms varies with type of dosage form. It includes physical 
appearance, strength, content uniformity and active ingredients etc. Various components 
present in dosage forms, including the presence of additives and multiple drug entities 
such as multi vitamins are some of the challenges encountered during the development of 
assay methods. 
1.6 SAMPLE PRETREATMENT (Lloyd R. Snyder et al., 1997) 
Drug samples from bulk dosage form need to be extracted with suitable solvent 
before being taken for analytical purposes. Sample pretreatment ensures such efficient 
procedures, which provide reproducible and homogeneous drug samples. It will further 
assure that the sample is (i) relatively free of interference (ii) will not damage the parts of 
the instruments (iii) will be compatible with assay procedures (such as solvent mobile 
phase etc.), such as pretreatment include Liquid-liquid extraction, solid phase extraction 
and membrane filtration. The selection of extraction solvent and the method of extraction 
are based on the solubility and recovery of the drug. 
1.6.1 The Importance of Sample Management (Kellner et al., 2004) 
 Whilst the analytical measurement approach may or may not influence the 
analytical result, the sample selected always does. The overall variance of the analytical 
result, s2total, is the sum of the individual contributory variances. This may be expressed 
as  
s2total = s2process + s2sampling + s2analytical 
However, the most difficult variance to estimate is the sampling variance. For this 
reason, it is important to have a structured approach to sampling and its nomenclature. 
The IUPAC sampling model covers both continuous or bulk goods and discrete or 
packaged goods. For a commercial perspective, it is extremely important that the sample 
is representative of the consignment if its value is to be determined on that basis. 
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1.7 ANALYTICAL METHOD (Douglas A. Skoog, et al., 2006) 
The analytical method maybe 
1) Qualitative analysis 
2) Quantitative analysis 
Qualitative analysis was performed to establish composition of natural/synthetic 
substances. These tests were performed to indicate whether the substance or compound is 
present in the sample or not. Various qualitative tests are detection of evolved gas, 
formation of precipitates, limit tests, colour change reactions, melting point and boiling 
point test etc. 
 
Quantitative analysis techniques are mainly used to quantify any compound or 
substance in the sample. These techniques are based in (a) the quantitative performance 
of suitable chemical reaction and either measuring the amount of reagent added to 
complete the reaction or measuring the amount of reaction product obtained, (b) the 
characteristic movement of a substance through a defined medium under controlled 
conditions, (c) electrical measurement and (d) measurement of some spectroscopic 
properties of the compound.  
 
The analytical methods are of two types 
 Classical methods  
 Instrumental methods 
In classical methods, for qualitative analysis, the analyte was extracted and treated 
with the reagent specific for a functional group to give a coloured reaction. In 
quantitative analysis, the amount of the analyte in determined by titrimetric method or by 
gravimetric method. 
The instrumental methods are based on the physical properties of the analyte such 
as the light absorption or emission, conductivity, mass to charge ratio, fluorescence, 
adsorption and partition etc. The instrumental methods are basically categorised as 
follows 
 Spectroscopic methods 
 Chromatographic methods 
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 Electro analytical methods 
 Thermal methods 
 Light scattering methods 
The instruments used for the instrumental methods basically consist of a source, 
system under study and the response. The source may be a light source, electrical source 
or heat source etc., as required by the instrument. The system under study is the analyte 
under study or any physical character of the analyte. The response is the unit in which the 
analytical signal from the analyte which is converted to an output signal for the 
interpretation. 
1.8 SPECTROSCOPIC METHODS 
Spectroscopy deals with the interaction of an analyte with electromagnetic 
radiation. The interaction of the electromagnetic radiation results in absorption or 
emission radiations. Based on the absorption or emission the spectroscopy is classified 
into, absorption spectroscopy and emission spectroscopy. 
1.8.1 Absorption Spectroscopy  
  (Gurudeep R. Chatwal, et al., 2008; Beckett and Stenlake, et al., 2007) 
When a beam of electromagnetic radiation is passed through an analyte, certain 
amount of the radiation is absorbed into the matter. The analyte after absorbing the 
radiation goes from the ground state to the excited state giving the absorption spectra. 
The various absorption spectroscopy include the UV-Visible absorption,                        
X-ray absorption, infrared absorption, microwave absorption, radio frequency absorption 
and atomic absorption, etc. 
1.8.1.1 Atomic Absorption 
In the atomic absorption spectra the electrons are excited from the lower energy 
state to a higher energy state by absorption of electromagnetic radiation. The atom 
absorbs the electromagnetic radiation of energy corresponding to the difference in energy 
between the higher and lower energy states of the absorbing atom. UV-Visible radiation 
can excite only the electrons in the outer most orbital, whereas the X-ray has the capacity 
to excite the electrons located in the inner shell near to the nuclei. 
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1.8.1.2 Molecular Absorption 
The molecular absorption spectra of polyatomic molecules are more complex than 
the atomic absorption spectra since the number of energy states are higher. The energies 
associated with a molecule are rotational energy, vibrational energy and electronic 
energy.  
   E = Eelectronic + Evibrational +Erotational 
The molecule absorbs electromagnetic radiation of energy corresponding to the 
difference in the energy of the ground state molecule and the excited state molecule. The 
difference in energy ∆E is given by, 
 ∆E = (Eelectronic + Evibrational +Erotational) excited – (Eelectronic + Evibrational +Erotational) ground 
The UV-Visible radiations and X-rays have the energy to induce the transition from the 
ground state to the excited state. 
1.8.2 Emission Spectroscopy 
Emission spectroscopy is the technique in which the wavelength of the photons 
emitted by an analyte due to the transition from higher energy level to lower energy on 
exposure to an electromagnetic radiation was studied. Each analyte emits a specific 
wavelength of radiation corresponding to the composition of the sample. The energy of 
the photons emitted is given by 
    Ephoton = hυ 
Where E is the energy of the photon, ν is the frequency and h is the Planck’s 
constant. The various instrumental techniques which are based on the measurement of the 
emitted radiation include flame photometry, fluorimetry, radiochemical methods. 
1.8.2.1Atomic Emission 
When an analyte is heated, it emits light characteristic of the atom present in it. 
For example, sodium when heated emits yellow light and potassium emits lilac light. 
When a metal is heated, the electrons in the outer orbital absorb the heat and goes to a 
higher energy state. The atom then comes back to the ground state by emitting the 
photons of light which has energy equal to the difference between the higher energy state 
and the lower energy state. The instrumental analytical technique, such as the flame 
emission spectroscopy works on the principle of measuring the photons of energy emitted 
by a thermally excited atom. 
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1.8.2.2 Molecular Emission 
When a beam of electromagnetic radiation falls on a molecular species, it absorbs 
the radiation and gets excited. The excited molecules are short lived and it fall back to the 
ground state immediately. The molecules in the excited sate have higher vibrational 
energy than that of the ground state. They emit the absorbed energy by the following 
ways, fluorescence and phosphorescence. 
The difference in the energy levels of the absorbed radiation, fluorescence and 
phosphorescence are as below 
∆Eabsorption > ∆Efluorescence > ∆Ephosphorescence 
 The analytical techniques spectrofluorimetry and phosphorimetry involves the 
principle of molecular emission. 
1.8.3 UV Spectroscopy (Sharma et al., 2009; Gurudeep R. Chatwal, et al., 2008) 
UV-visible spectroscopic methods are based on the type of 
chromophore/functional group present in the drug moiety. Multi component systems are 
also easily analysed by means of spectral isolation. Spectroscopic methods are widely 
used as tools for quantitative analysis, characterization and quality control in the 
pharmaceutical, agricultural and biomedical fields 
The UV spectroscopy is one of the most widely used instrumental analytical 
techniques for the analysis of pharmaceuticals. The UV region extends from 190 nm to 
380 nm. The instrument used to measure the intensity of the UV radiation absorbed or 
transmitted is known as the UV - Visible spectrophotometers. A molecule can absorb the 
UV radiation only when the energy of the radiation matches the energy that was required 
to induce electronic transition in the molecule. 
1.8.3.1 Laws of Absorption 
When a beam of UV light is allowed to pass through a substance which absorbs 
the UV light, the intensity of the transmitted light was lesser than the incident light. The 
reduction of the intensity is may be due to reflections on the surface of the cell, scattering 
of light by macro molecules and absorption. 
The two important laws which govern the UV spectroscopy are the Lambert’s law 
and Beer’s law. Lambert’s law states that the intensity of the light decreases 
exponentially with decrease in the thickness of the medium through which it passes. 
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Beer’s law states that the intensity of the light decreases exponentially with increase in 
the concentration of the absorbing substance. 
The two laws where combined to form the Beer-Lambert’s law, which is given by the 
equation 
    A = abc 
Where, A is the absorbance 
 a is the absorptivity 
 b is the path length 
 c is the concentration. 
 The absorptivity is defined as, the absorbance of a substance at a specific 
wavelength of 1 g/100 ml solution in a 1cm cell. 
1.8.3.2 Deviation of Beer’s Law 
When the absorbance is plotted against concentration, a straight line passing 
through the origin should be obtained. But there is always a deviation from the linear 
relationship in the plot of absorbance versus concentration. The deviation in the Beer’s 
law may be due to anyone of the following reasons. 
The presence of foreign substance affects the light absorption and alters the 
extinction coefficient. 
 Due to dissociation or association of the molecule. Example, benzyl alcohol in 
chloroform exists as a polymer. The monomer absorbs at lower wavelength and 
the polymer at higher wavelength. 
 Due to presence of foreign substance which absorbs at the same wavelength as the 
analyte. 
 If monochromatic light is not used. 
 Due to undesirable radiations falling on the detector. 
1.8.3.3 Transitions in Organic Molecules  
   (Sharma et al., 2009; Gurdeep R. Chatwal, et al., 2008) 
The absorption in the ultraviolet region results in the transition of the valence 
electron form the ground level to the excited level. The three types of electrons involved 
in the transition are 
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σ-electrons: These are involved in the formation of saturated bonds. The energy required 
for the excitation of the electrons is more than that of the UV radiations. Hence these 
electrons do not absorb near UV radiation. 
π-electrons: These are involved in the formation of unsaturated bonds. 
Example: Dienes, trienes and aromatic compounds. It absorbs radiation in near UV 
region. 
n-electrons: These are the lone pair of electrons present in atoms such as oxygen, 
nitrogen etc., in a molecule. They can be excited by both UV and Visible radiations. 
The various types of transitions are 
σ →σ* 
 n→σ* 
π → π * 
  n→π* 
 
(http://www.pharmatutor.org/pharma-analysis/analytical-aspects-of-uv-visible-
spectroscopy/types-of-electrone-transition.html) 
The energy required for the various types of transitions are  
σ→σ* > n→σ* > π → π * > n→ π *  
1.8.3.4 σ→σ* transitions 
These transitions occur in saturated hydrocarbons with single bonds and no lone 
pair of electrons. The energy required for this type of transition is very high because of 
the strong sigma bond formed by the valence electrons. Thus, the transitions occur at very 
short wavelength. The saturated hydrocarbons such as methane, ethane, propane etc. 
absorbs at 126 -135 nm region of the UV region. Hence these compounds are used as 
solvents in UV spectroscopy. 
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1.8.3.5 n → σ* transitions 
Saturated compounds with lone pair of electrons show n→σ* transitions in 
addition to σ→σ* transitions. The energy required for the n→σ* transition is lesser than 
the energy required for σ→σ* transitions. The energy required for n→σ* transition, in 
alkyl halides, decreases with increase in the size of the halogen atom. Alcohols and 
amines forms hydrogen bonding with the solvent hence require higher energy for the 
transitions. 
1.8.3.6 π → π * transitions 
These transitions occur in unsaturated compounds containing double or triple 
bonds and also in aromatic compounds. Lower energy is required for these transitions and 
hence a longer wavelength causes the excitation of the molecule. 
1.8.3.7 n→ π* transitions 
These transitions occur in compound which contains oxygen, nitrogen, sulphur 
and halogens because of the presence of free lone pair of electrons. These transitions 
require least amount of energy and hence they occur in UV and Visible region. Saturated 
carbonyl compounds shows two types of transitions, low energy n→ π* transitions 
occurring at longer wavelength and high energy n→ π* transitions occurring at lower 
wavelength. The shifts in the absorption of the carbonyl compounds are due to the 
polarity of the solvent. 
1.8.4 Transition Probability (Gurudeep R. Chatwal, et al., 2008) 
It is not essential that, when a compound is exposed to UV light, transition of the 
electron should take place. The probability that an electronic transition should take place 
depends on the value of extinction coefficient. The transitions are classified as allowed 
transition and forbidden transition. 
1.8.4.1 Allowed Transitions 
The transitions having εmax value greater than 104 are called allowed transitions. 
They generally arise due to the π → π * transitions. For example, 1, 3 – butadiene 
exhibits absorption maximum at 217 nm and has εmax value of 21000 represents allowed 
transitions. 
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1.8.4.2 Forbidden Transitions 
These transitions have εmax value less than 104. They occur due to n→ π* 
transitions. Example, saturated carbonyl compound (R-C=O) shows absorption near 290 
nm and εmax value less than 100 represent forbidden transitions. 
1.8.5 Chromophore 
These are groups or structure which is responsible to impart colour to the 
compound. The presence of chromophore is responsible for the absorption of UV 
radiation by any compound. The groups include nitro group, amine groups, double bonds, 
triple bonds, etc.  
There are two types of chromophore 
 Groups containing π electrons and undergoes π → π * transitions. Example: 
ethylene, acetylenes 
 Groups containing π electrons and n electrons. They undergo two types of 
transition like π → π * transitions and n→ π* transitions. Example:- carbonyls, 
nitriles, azo compounds etc. 
1.8.6 Auxochrome 
 Any groups which do not itself act as a chromophore but its presence brings a 
shift in the position of absorption maximum. Chromophores are unsaturated whereas the 
auxochromes are covalently saturated. The auxochromes are of two types 
Co-ordinately unsaturated- (NH2, -S- groups containing lone pair of electrons). 
Co-ordinately saturated- (NH3+ groups). 
1.8.7 Absorption and Intensity shifts 
1.8.7.1 Bathochromic shift or Red shift 
The shift in the absorption maximum of a compound, due to the presence of  
certain auxochromes, towards longer wavelength is called as the bathochromic shift. 
1.8.7.2 Hypsochromic shift or Blue shift 
The shift in the absorption maximum to shorter wavelength is called 
Hypsochromic shift. The shift is due to solvent effect or removal of conjugation in a 
molecule. 
1.8.7.3 Hyperchromic effect 
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The increase in intensity of absorption by inclusion of an auxochrome to a system 
is hyperchromic shift. 
1.8.7.4 Hypochromic shift 
The decrease in the intensity of absorption is due to the distortion of the geometry 
of the molecule. 
1.8.8 Solvent Effect 
The solvent used for the spectral analysis should not interfere in the absorbance of 
the analyte. It means that the solvent should not have any absorbance in the region under 
investigation. Based on the polarity of the solvent used the intensity of the absorption 
changes for a particular analyte. The α, β – unsaturated carbonyl compounds shows two 
different types of transitions 
n→ π* transition  
The increase in polarity moves the absorption maximum to a shorter wavelength. 
The ground state is more polar when compared to the excited state. 
π → π * transitions 
The increase in polarity moves the absorption maximum to longer wavelength. 
Only lesser energy is required for this transition and hence shows red shift. 
1.8.9 Choice of Solvent 
There are two important requirements a solvent must satisfy to be used as a 
solvent in UV spectroscopy.  
They are  
 It should be transparent throughout the region of UV under investigation 
 It should not interact with the solute molecules and should be less polar. 
1.8.10 Instrumentation 
The components of a UV-Visible spectrophotometer are 
 Light source 
 Monochromators 
 Sample cell 
 Detectors 
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Light source 
 The various source of light used in the spectrophotometer are tungsten lamp, 
hydrogen discharge lamp, deuterium lamp, xenon arc lamp and mercury arc lamp. The 
most commonly used lamp is the deuterium discharge lamp. 
Monochromators 
 The monochromators are used to disperse the light for the required wavelength. 
The monochromators consists of three units entrance slit, dispersing element and exit slit. 
The dispersing unit may be filters, prisms or gratings. The fused silica prisms and quartz 
prisms are commonly used in UV spectrophotometers. 
Sample cell 
 The cell must be transparent throughout the wavelength region of study. The cells 
are made of fused glass or fused silica or quartz. The glass cells are not used since they 
absorb in the UV region. Quartz cells are commonly used. 
Detectors 
 The detectors employed are barrier layer cells, photo emissive tubes, photodiodes 
and photomultiplier tubes. Photodiodes are commonly used in the instrument.  
1.9.12 Spectrophotometers 
There are two designs of spectrophotometer. They are single beam 
spectrophotometer and double beam spectrophotometer. 
Single beam system 
 Light given off from the source 
 Lens gathers the light and focuses on the monochromators 
 The light of specific wavelength comes out of the monochromator 
 Radiation passes through the sample in the sample cell and to the detector 
 Detector measures the intensity of the light reaching it. 
 
UV-Visible Single beam spectrophotometer (chemistry.adelaide.edu.au) 
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Double beam system 
 Radiation from source falls on the monochromator 
 The radiation of the required wavelength pass out of the exit slit reaches the 
rotating disc 
 Rotating disc splits the beam into two, one passes through the sample cell and the 
other passes through the reference cell. 
 The light beam falls on the detector 
 Detector measures the intensity of the light. 
 
 
Double beam UV-Visible spectrophotometer (Chemguide.co.uk) 
1.8.11 Quantitative Analysis of Single Component (Beckett and Stenlake, et al., 2007) 
 The assay of an analyte is done by dissolving the analyte in a suitable solvent and 
measuring the absorbance of the solution at the required wavelength. The selected 
wavelength is the absorbance maximum of the analyte in that particular solvent. The 
concentration of the analyte can be determined by 
 Use of absorptivity value 
 Use of calibration graph 
 Single or double point standardization 
1.8.11.1 Absorptivity Value Method 
 This method is usually followed in official books such as Indian Pharmacopoeia, 
British Pharmacopoeia etc. The advantage of the method is, the preparation of standard 
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solutions of reference substance is not required for the calculation of the concentration of 
the analyte. 
1.8.11.2 Calibration Graph Method 
 In this method, a series of linear concentration solutions of the reference solutions 
are prepared and the value of absorbance is plotted against the concentration of the 
reference solution. From the graph the absorbance of the sample solution is plotted and 
the concentration is found. 
1.8.11.3 Single Point or Double Point Standardization 
 In single point standardization, the standard and the sample solutions are prepared 
under same identical condition. Also, the standard and the sample concentration are 
almost equal. Then after the measurement of absorbance the following formula is applied 
to find the unknown sample concentration 
ܥ௧௘௦௧ = ܣ௧௘௦௧ܣ௦௧ௗ × ܥ௦௧ௗ 
 Double point standardization is used when there is a linear but non proportional 
relationship between concentration and absorbance. The concentration of one of the 
standard is higher and the concentration of other is lower than that of the standard. 
ܥ௧௘௦௧ = (ܣ௧௘௦௧ − ܣ௦௧ௗଵ)(ܥ௦௧ௗଵ − ܥ௦௧ௗଶ) + ܥ௦௧ௗଵ(ܣ௦௧ௗଵ − ܣ௦௧ௗଶ)ܣ௦௧ௗଵ − ܣ௦௧ௗଶ  
1.8.12 Assay of Substance in Multi Component Samples 
 The spectrophotometric assay of drugs rarely involves the measurement of 
absorbance of sample containing only one absorbing component. The pharmaceutical 
analyst frequently encounters the situation where the concentration of one or more 
substances is required in samples known to contain other absorbing substances which 
potentially interfere in the assay. Alternatively, interference which is difficult to quantify 
may arise in the analysis of formulations from manufacturing impurities, decomposition 
products and formulation excipients. Unwanted absorption from these sources is termed 
irrelevant absorption and, if not removed, imparts a systematic error to the assay of the 
drug in the sample. 
The basis of all the spectrophotometric techniques for multi component sample is the 
property that at all wavelengths; 
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 The absorbance of a solution is the sum of absorbance’s of the individual 
components; or 
 The measured absorbance is the difference between the total absorbance of 
the solution in the sample cell and that of the solution in the reference cell. 
 Multi component analysis is done when the sample contains more than one analyte to 
be quantified in the sample. In such methods one of the analyte may be taken as 
interferent and the absorbance of the interferent reduced to find the true absorbance of the 
analyte. Similarly the absorbance of the other analyte is found by taking the first analyte 
as the interferent. The various methods used are as follows. 
 Simultaneous equation method 
 Absorption ratio method 
 Geometric correction method 
 Orthogonal polynomial method 
 Difference spectroscopy 
 Area under curve method  
 Absorbance ratio method 
 Derivative spectrophotometry 
Simultaneous Equations method 
 If a sample contains two absorbing drugs (X and Y) each of which absorbs at the 
max of the other, it may be possible to determine both drugs by the technique of 
simultaneous equations (Vierodt’s method) 
 The information required is: 
a. The absorptivities of X at 1 and 2, ax1 and ax2 respectively. 
b. The absorptivities of Y at 1 and 2, ay1 and ay2 respectively. 
c. The absorbances of the diluted sample at 1 and 2, A1 and A2 respectively. 
Let Cx and Cy be the concentrations of X and Y respectively for diluted sample. 
 Two equations are constructed based upon the fact that at 1 and 2 the absorbance 
of the mixture is the sum of individual absorbances of X and Y. 
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At 1 
A1 = ax1bcx + ay1bcy    (1) 
At 2 
A1 = ax2bcx + ay2bcy    (2) 
 
For measurements in 1 cm cells, b = 1 
Rearrange eq. (2) 
ܿ௬ = ܣଶ − ܽ௫ଶܿ௫ܽ௬ଶ  
Substituting for cy in eq. (1) and rearranging gives 
ܥ௫ = ܣଶܽ௬ଵ − ܣଵܽ௬ଶܽ௫ଶܽ௬ଵ − ܽ௫ଵܽ௬ଶ 
And 
ܥ௬ = ܣଵܽ௫ଶ − ܣଶܽ௫ଵܽ௫ଶܽ௬ଵ − ܽ௫ଵܽ௬ଶ 
 As an exercise you should derive modified equations containing a symbol (b) for 
path length, for application in situations where A1 and A2 are measured in cells other than 
1 cm path length. 
Criteria for obtaining maximum precision, based upon absorbance ratios, have 
been suggested that place limits on the relative concentrations of the components of the 
mixture.  The criteria are that the ratios 
ܣଶ ܣଵ⁄
ܽ௫ଶ ܽ௫ଵ⁄
ܽ݊݀ ܽ௬ଶ ܽ௬ଵ⁄
ܣଶ ܣଵ⁄
 
Should lie outside the range 0.1 - 2.0 for the precise determination of Y and X 
respectively, these criteria are satisfied only when the max of the two components are 
reasonably dissimilar. An additional criterion is that the two components do not interact 
chemically, thereby negating the initial assumption that the total absorbance is the sum of 
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the individual absorbance.  The additive of the absorbance should always be confirmed in 
the development of a new application of this technique. 
Absorbance Ratio Method 
 The absorbance ratio method is a modification of the simultaneous 
equations procedure.  It depends on the property that, for a substance which obeys Beer’s 
Law at all wavelengths, the ratio of absorbances at any two wavelengths is a constant 
value independent of concentration or path length.  For example, two different dilutions 
of the same substance give the same absorbance ratio A1/A2, 2.0.  In the USP, this ratio 
is referred to as a Q value.  The British Pharmacopoeia also uses a ratio of absorbance at 
specified wavelengths in certain confirmatory tests of identity.  
 In the quantitative assay of two components in admixture by the absorbance ratio 
method, absorbances are measured at two wavelengths one being the max of one of the 
components (2) and the other being a wavelength of equal absorptivity of the two 
components (1), i.e., an iso-absorptive point. Two equations are constructed as described 
above for the method of simultaneous equation (eq. (1) and eq.(2)). Their treatment is 
somewhat different, however, and uses the relationship ax= ay1 at (1). Assume b=1 cm. 
A1 = ax1cx + ax1CY    (5) 
ܣଶ
ܣଵ
= ܽ௫ଶܿ௫ + ܽ௬ଶܿ௬
ܽ௫ଵܿ௫ + ܽ௫ଵܿ௬  
Divide each term by cx + cy and let Fx = cx/(cx + cy) and Fy = cy/(cx + cy) i.e. Fx and Fy are 
the fractions of X and Y respectively in the mixture: 
ܣଶ
ܣଵ
= ܽ௫ଶܨ௫ + ܽ௬ଶܨ௬
ܣ௫ଵܨ௫ + ܽ௫ଵܨ௬ 
But Fy = 1 – Fx’ 
ܣଶ
ܣଵ
= ܨ௫ܽ௫ଶ − ܨ௫ܽ௬ଶ + ܽ௬ଶ
ܽ௫ଵ
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ܣଶ
ܣଵ
= ܨ௫ܽ௫ଶ
ܽ௫ଵ
−
ܨ௫ܽ௬ଶ
ܽ௬ଵ
+ ܽ௬ଶ
ܽ௬ଵ
 
Let ܳ௫ = ܽ௫ଶܽ௫ଵ ,ܳ௬ ܽ௬ଶܽ௬ଵ ܽ݊݀ ܳெ ܣଶܣଵ 
QM = Fx(Qx – Qy) + Qy 
ܨ௫ = ொಾିொ೤ொೣିொ೤    (6) 
 Equation 6 gives the fraction, rather than the concentration of X (and 
consequently of Y) in the mixture in terms of absorbance ratios. As these are independent 
of concentration, only approximate, rather than accurate, dilutions of X, Y and the sample 
mixture are required to determine Qx, Qy and QM respectively. 
A1 = ax1 + ( cx + cY) 
ܿ௫ + ܿ௬ =  ܣଵ         ܽ௫ଵ  
From eq. (6) 
ܿ௫
݂2ܿ௫ + ܿ௬ =  ܳ௠ − ܳ௬ܳ௫ − ܳ௬ܾ7. 
ܿ௫
ܣଵ ܽ௫ଵ⁄
= ܳெ − ܳ௬
ܳ௫ − ܳ௬
 
                ܿ௫ = ொ೘ିொ೤ொೣିொೊ . ஺భ௔ೣభ               (7) 
Equation 7 gives the concentration of X in terms of absorbance ratios, the 
absorbance of the mixture and the absorptivity of the compounds at the iso-absorptive 
wavelength.  Accurate dilutions of the sample solution and of the standard solutions of X 
and Y are necessary for the accurate measurement of A1 and ax1 respectively. 
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 Geometric Correction Method 
 A number of mathematical correction procedures have been developed which 
reduce or eliminate the background irrelevant absorption that may be present in samples 
of biological origin. The simplest of these procedures is the three-point geometric 
procedure, which may be applied if the irrelevant absorption is linear at the three 
wavelengths selected. 
Corrected absorbance, D = 
௬(஺ଶି஺ଷ)ା ௭(஺ଶି஺ଵ)(௒ା௓)(ଵି௥)  
Orthogonal Polynomial Method 
 The technique of orthogonal polynomials is another mathematical correction 
procedure which involves more complex calculations than the three-point correction 
procedure.  The basis of the method is that an absorption spectrum may be represented in 
terms of orthogonal functions as follows 
A() = p0P0() + p1P1() + p2P2()….pnPn () 
Where, A = Absorbance  
   = Wave length 
  Po (), P1 (), P2 ()….Pn () represent the polynomial coefficient 
 Each coefficient is proportional to each other. These polynomials represent a 
series of fundamental shapes and the contribution that each shape, e.g.P2 makes to the 
absorption spectrum is defined by the appropriate coefficient, e.g. p2 for P2.  The 
coefficients are proportional to the concentration of the absorbing analyte, and a modified 
Beer – Lambert equation may be constructed: 
pj = jbc 
  For example, when b is 1 cm and concentration of the analyte (c), is in g/ dl. 
When irrelevant absorption so, present in a sample solution, the calculated coefficient (pi) 
comprises the coefficients of the analyte and of the irrelevant absorption (Z).  
  Thus, 
Pj = αjc + pj(Z) 
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 Where, 
  Pj = polynomial coefficient 
  aj = proportionality constant 
  b = path length 
  c = concentration 
With the correct choice of polynomial, number of wavelengths and the wavelength 
interval, the contribution from the irrelevant absorption may be negligible. In general, a 
quadratic (P2) polynomial eliminates linear or almost linear irrelevant absorption and a 
cubic (P3) polynomial eliminates parabolic irrelevant absorption. 
 The segment of the spectrum of the drug between 1and 8 shows a minimum 
around 3 and a maximum around 5. Its shape may therefore be represented by a cubic 
polynomial. The irrelevant absorption is a simple parabolic curve which does not contain 
a cubic contribution. The coefficient (P3) of the polynomial for each set of eight 
absorbances (A1……..A8) is calculated from: 
P 3 = [(-7)A1 + (+5)A2 + (+7)A3 + (+3)A4 + (-3)A5 + (-7)A6 + (-5)A7 + (+7)A8] 
Where the factors are those of an eight –point cubic polynomial obtained from standard 
texts of numerical analysis (e.g. Fischer and Yates, 1953). The contribution of the 
irrelevant absorption to the coefficient of the polynomial of the sample is eliminated 
(Table 7.2) by the selection of these parameters, and the concentration of the drug in the 
sample may be calculate with reference to a standard solution of the drug, from the 
proportional relationship that exists between the calculated P3 value and concentration. 
 The accuracy of the orthogonal functions procedure depends on the correct choice 
of polynomial order and set of wavelengths. Usually, quadratic or cubic polynomials are 
selected depending on the shape of the absorption spectra of the drug and the irrelevant 
absorption. The set of wavelengths is defined by the number of wavelengths, the interval, 
and the mean wavelength of the set (m). approximately linear irrelevant absorption is  
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normally eliminated using six to eight wavelengths, although many more, up to 20, 
wavelengths may be required if the irrelevant absorption contains high frequency 
components. The wavelength interval and m are best obtained from convoluted 
absorption curve. This is a plot of the coefficient (Pj) for a specified order of polynomial, 
a specified number of wavelengths and a specified wavelength interval (on the ordinate) 
against the m of the set of wavelengths. The optimum set of wavelengths corresponds 
with a maximum or minimum in the convoluted curve of the analyte and with a 
coefficient of zero in the convoluted curve of the irrelevant absorption. In favourable 
circumstances the concentration of an absorbing drug in admixture with another may be 
calculated if the correct choice of polynomial parameters is made, thereby eliminating the 
contribution of one drug from polynomial of the mixture. For, example, the selective 
assay phenobarbitone, combined with phenytoin in a capsule formulation using a six-
point quardratic polynomial, has been reported. 
 The determination of the optimum set of wavelengths is readily accomplished 
with the aid of a microcomputer. A suitable exercise is to write a program to compute and 
plot the data for convoluted spectrum.  
Difference Spectrophotometry 
 The selectivity and accuracy of spectrophotometric analysis of samples containing 
absorbing interferents may be markedly improved by the technique of difference 
spectrophotometry. The essential feature of a difference spectrophotometric assay is that 
the measured value is the difference absorbance (A) between two equimolar solutions of 
the analyte in different chemical forms which exhibit different spectral characteristics. 
The criteria for applying difference spectrophotometry to the assay of a substance in the 
presence of other absorbing substances are that: 
 reproducible changes may be induced in the spectrum of the analyte by the 
addition of one or more reagents 
 the absorbance of the interfering substances is not altered by the reagents. 
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 The simplest and most commonly employed technique for altering the spectral 
properties of the analyte is the adjustment of the pH by means of aqueous solutions of 
acid, alkali or buffers.  The ultraviolet-visible absorption spectra of many substances 
containing ionisable functional groups, e.g. phenols, aromatic carboxylic acids and 
amines, are dependent on the state of ionization of the functional groups and 
consequently on the pH of the solution. 
 The absorption spectra of equimolar solutions of Phenylephrine, a phenolic 
sympathomimetic agent, in both 0.1M hydrochloric acid (pH 1) and                           
0.1M sodium hydroxide (pH 13) are shown in figure.  The ionization of the phenolic 
group in alkaline solution generates an additional n (non-bonded) electron that interacts 
with the with the ring π electrons to produce a bathochromic shift of the max from 
271nm in acidic solution to 291 nm and an increase in absorbance at the (hyperchromic 
effect).  The difference absorption spectrum is a plot of the difference in absorbance 
between the solution at pH 13 and that at pH 1 against wavelength. It may be generated 
automatically using a double-beam recording spectrophotometer with the solution at     
pH 13 in the sample cell and the solution at pH 1 in the reference pH 13 in the sample 
cell and the solution at pH 1 in the reference cell. At 257 and 278 nm both solutions have 
identical absorbance and consequently exhibit zero difference absorbance. Such 
wavelengths of equal absorptivity of the two species are called isobestic or iso-absorptive 
points.  Above 278 nm the alkaline solution absorbs more intensely than the acidic 
solution and the A is therefore positive. Between 257 and 278 nm it has a negative 
value.   The measure value in a quantitative difference spectrophotometric assay is the 
A at any suitable wavelength measured to the baseline, e.g. A1 at 1 or amplitude 
between an adjacent maximum and minimum, e.g. A1 at 2 and 1. 
At 1 A = Aalk – Aacid 
 Where Aalk and Aacid are the individual absorbances in 0.1M sodium hydroxide 
and 0.1M hydrochloric acid solution respectively. If the individual absorbance, and are 
proportional to the concentration of the analyte and path length, the also obeys the Beer – 
Lambert Law and a modified equation may be derived 
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Where a is the difference absorptivity of the substance at the wavelength of 
measurement. 
 If one or more other absorbing substances is present in the sample which at the 
analytical wavelength has identical absorbance in the alkaline and acidic solutions, its 
interference in the spectrophotometric measurement is eliminated. The selectivity of the 
A procedure depends on the correct choice of the pH values to induce the spectral 
change of the analyte without altering the absorbance of the interfering components of 
the sample. The use of 0.1M sodium hydrochloric acid to induce the A of the analyte is 
convenient and satisfactory when the irrelevant absorption arises from pH intensive 
substances.  
Area Under the Curve Method 
 From the spectra obtained for calculating the simultaneous equation, the area 
under the curve were selected at a particular wavelength range for both the drugs were 
each drug  have its absorption. The “X” values of the drugs were determined at the 
selected AUC range. The “X” value is the ratio of area under the curve at the selected 
wavelength range with the concentration of the component in mg/ ml. These “X” values 
were the mean of six independent determinations. A set of two simultaneous equations 
were obtained by using mean “X” values. And further calculations are carried out to 
obtain the concentration of each drug present in the sample. 
Absorption Correction Method 
 The method can be used to calculate the concentration of component of interest 
found in a mixture containing it along some unwanted interfering component. The 
absorption different between two points on the mixture spectra is directly proportional to 
the concentration of the component to be determined irrespective of the interfering 
component. If the identity, concentration and absorptivity of the absorbing interferences 
are known, it is possible to calculate their contribution to the total absorbance of a 
mixture. The concentration of the absorbing component of interest is then calculated from 
the corrected absorbance (total absorbance minus the absorbance of the interfering 
substance) in a usual way. The data required for the construction of absorbance corrected 
for interference are 
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The max of the drugs should be found out by using reference standards of the drugs. 
The calibration curve is plotted for each drug and linearity range should be found out. 
At one wavelength, one of the drugs shows no absorbance. Hence the other drug was 
calculated without any interference. 
The absorbance values of every drug at the two wave lengths should be measured and the 
absorptivity values should be calculated. 
In another wavelength, the absorbance corrected for another drug and the first drug was 
determined. 
 
Derivative Spectrophotometry 
 In this method, the normal spectrum is converted into derivative spectrum of 
higher orders such as first order, second order, etc. The transformations that occur in the 
derivative spectra are understood by reference to a Gaussian band which represents an 
ideal absorption band. 
 The first order derivative spectrum is a plot of the rate of change of absorbance 
with wavelengths against wavelength, i.e. a plot of the slope of the fundamental spectrum 
against wavelength or a plot of dA/d vs . At 2 and 4, the maximum positive and 
maximum negative slope respectively in the D1 spectrum. The max at 3 is a 
wavelength of zero slope and gives dA/d = 0, i.e. a cross-over point, in the D1 spectrum. 
 The second derivative (D2) spectrum is a plot of the curvature of the Dº spectrum 
against wavelength. The maximum negative curvature at 1 and 5 the maximum 
positive curvature in the Dº spectrum gives two small maxima called ‘satellite’ bands in 
the D2 spectrum. At 2 and 4 the wavelengths of maximum slope and zero curvature in 
the Dº spectrum correspond with cross-over points in the D2 spectrum. 
 In summary, the first derivative spectrum of an absorption band is characterised 
by a maximum, a minimum, and a cross –over point at the max of the absorption band. 
The second order derivative spectrum is characterised by two satellite maxima and an 
inverted band of which the minimum corresponds to the max of the fundamental band. 
  The advantages of derivative method are the higher resolution and band width 
discrimination. This advantage permits the determination of analyte even in the presence 
of non specific interferents. The higher resolution and band width discrimination 
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increases with the increase in the order of derivatization. This provides much better finger 
prints than traditional working spectrum (Hassan et al., 2000 and Gindy et al., 2000) But 
the signal to noise ratio decreases with the increase in derivative order. 
1.9 Chromatographic Methods  
  (Gurudeep R. Chatwal, et al., 2008; Beckett and Stenlake, et al., 2007) 
Chromatography is the science which deals with the separation achieved by the 
distributing the analyte between two phases, a stationary phase and a mobile phase based 
on the principle of adsorption and partition. 
1.9.1 Mechanism 
The various mechanisms in the chromatography are 
 Adsorption chromatography 
 Partition chromatography 
 Ion exchange chromatography 
 Gel chromatography 
1.9.1.1 Adsorption Chromatography 
 This type of chromatography contains a solid stationary phase and a liquid or 
gaseous mobile phase. Paper Chromatography, Thin Layer Chromatography, High 
Performance Liquid Chromatography work based on the principle of adsorption. 
1.9.1.2Partition Chromatography 
 In this the stationary phase is a liquid and the mobile phase maybe a liquid or a 
gas. Gas – Liquid Chromatography, Liquid – Liquid Chromatography works on the 
principle of partition. 
1.9.1.3 Ion Exchange Chromatography 
 Solid stationary phase with replaceable ions and ionic liquid mobile phase are 
features of ion exchange chromatography. 
1.9.1.4 Gel Chromatography 
 An inert gel acts as the stationary phase and a liquid mobile phase are the features 
of the gel chromatography. They separate the analyte according to their sizes. 
1.9.2 Techniques 
 The various techniques of development of chromatogram are frontal analysis, 
elution analysis and displacement analysis 
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1.9.2.1 Frontal Analysis 
 The sample solution is allowed to pass through the column continuously; the 
strongly adsorbed solutes are retained in the column whereas the less strongly adsorbed 
solutes are washed off easily. 
1.9.2.2 Elution Analysis 
 A small amount of the sample is placed at the top of the column and then the 
eluant is allowed to flow through the column. The solutes elute out of the column based 
on the partition coefficient of the solutes. 
1.9.2.3 Displacement Analysis 
 The sample solution is introduced at the top of the column and the elution is made 
by using a solution containing a strongly adsorbing solute. The strongly adsorbed solute 
displaces the adsorbed analyte from the column. Hence this method is called the 
displacement analysis and the strongly adsorbing solute is called as the displacing agent. 
1.9.3 High Performance Thin Layer Chromatography (Sethi, et al., 1996)                                                                                                                             
High Performance Thin Layer Chromatography is a versatile separation technique 
and is official in most of the Pharmacopoeias for determining content uniformity, purity 
profile, assay value and dissolution rates in unlimited number of monographs. It is 
precisely for these reasons that almost every laboratory today is equipped HPLC system. 
However, it cannot be denied that more than often, the systems are working 
beyond their capacities and mostly dedicated who would like to change a well running 
stabilized column and prepare fresh solutions only because few assorted samples even 
though urgent are required to be analyzed.  
1.9.3.1 Various Steps Involved in HPTLC 
 Selection of HPTLC plates and sorbent.  
 Samples preparation including any clean up and  
 Pre-chromatographic derivatization. 
 Application of sample.  
 Development. 
 Detection including post-chromatographic derivatization.  
 Quantification. 
 Documentation.      
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1.9.3.2 Criteria for Identification of an Analyte by HPTLC 
 Rf value of an analyte should agree ± 3 % compared to standard material used 
under similar conditions. 
 Visual appearance of the analyte should be indistinguishable from that of 
standard material.  
 Centre of the spot nearest to that due to analyte should be separated from it by at 
least half the sum of analyte spot diameter. 
 For conforming the identity, co-chromatography is mandatory, as a result, only 
the spot supposed to be due to analyte should be visible and no additional spot 
appear. 
 Whenever spectrum detection is used, maximum absorption wavelength of the 
sample and standard should be same within limits of resolution of detection 
system and UV spectra should not be visibly different from that of the standard 
material. 
1.9.3.3 Factors Influencing the HPTLC Separation and Resolution of Spots 
 Type of stationary phase, its particle size and activity  
 Type of plates   
 Layer thickness 
 pH of the layer 
 Binder in the layer 
 Mobile phase 
 Solvent purity 
 Type and size of developing chamber  
 Degree of chamber saturation  
 Solvent for the sample preparation  
 Sample volume spotted 
 Size of initial spot and gradient  
 Temperature and relative humidity  
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Method Development for HPTLC 
                 
 
         Selection and Optimization of            Selection of Stationary Phase;  
                  Mobile phase                                   Prewashing of Layer 
 
          In situ Pre Chromatographic           Pre Conditioning /saturation of                  
                       Derivatization                                           Layer  
 
 
 
 
 
      UV-Visible /Fluorescent              Post Chromatographic  
                           Detection                                Derivatization  
 
 
1.10 Selection of an Analytical Method (Douglas A. Skoog, et al., 2006) 
 To select an analytical method, it is essential to clarify the nature of analytical 
problem-the accuracy required, quantity of sample available, concentration range of the 
analyte, interfering substance, physicochemical properties of sample matrix and number 
of samples to be analyzed. 
1.11 Performance Characteristic of Instruments 
 The performance characteristic of the instrument such as precision, bias, 
sensitivity detection limit, dynamic range and selectivity are considered before selecting 
the method itself. The method should also be fast, easy, convenient and cost effective.   
1.12 Development of Analytical Method  
 Due to advances in high throughput organic synthesis and discovery teams, there 
is a great increase in the number of analogues introduced for the absorption, distribution, 
metabolism and excretion properties. 
Sample Preparation 
Application of Sample 
Development of Chromatogram 
Detection of Analyte 
Quantitative Evaluation 
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Fixed dose combinations forms the main stay in clinical management of many 
acute and chronic disease as they offer several advantages over single products with 
respect to storage, prescribing, dispensing patients, use, consumption and synergistic 
effect in disease management 
1.13 New Applications in Analytical Technique (Regina M.B.O Duarte et al., 2012) 
A new chromatographic response function (CRF2D) is proposed and tested for the 
estimation of the quality index of separation in comprehensive two-dimensional liquid 
chromatography (2D-LC) of complex organic mixtures. This objective function is based 
on the concept of peak purity for one-dimensional liquid chromatography, which has 
been redefined for 2D-LC. The new CRF2D also includes other separation quality criteria, 
namely the number of 2D peaks appearing in the chromatogram and the analysis time. To 
compute the peak purity for a given 2D peak, three important steps have been tackled in 
this study: (a) the development of an alternative algorithm for detecting 2D peaks 
automatically from real experimental 2D-LC data; (b) the application of a mathematical 
model to fit the obtained chromatographic data; and (c) the estimation of the volume of 
the overlapping region between two or more 2D peaks. The capability of the new 
function to qualify the overall separation degree that it is attained under different 
chromatographic conditions was further assessed through a 2D-LC study of a mixture of 
compounds. 
Screening analysis for detection of selected drugs of abuse and psychoactive 
medical drugs in whole blood using solid phase extraction and UPLC-TOFMS. 
1.14 VALIDATION (www.askaboutvalidation.com/forum/showthread.php?t=1175) 
 The word “Validation” means “Assessment” of validity or action of proving 
effectiveness. 
Validation as defined by different agencies 
USFDA- According to this “validation” is the process of establishing documented 
evidence which provides a high degree of assurance that a specific process will 
consistently produce a product meeting its predetermined specifications and quality 
attributes. 
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WHO- Defines validation as an action of providing any procedure process equipment 
material, activity or system actually leads to the expected results. 
EUROPEON COMMITTEE- Defines validation as an action of providing in a 
accordance with the principles of GMP that any procedure, process material and activity 
or system actually leads to expected results 
1.14.1 Method Validation 
 This process consists of establishment of the performance characteristics and the 
limitations of the method 
Method performance parameters are determined using equipment that is  
 Within specification 
 Working correctly 
 Adequately calibrated 
Method validation is required when 
 New method is been developed 
 Revision of already existed methods 
 When established method are used in different laborarties and analyst 
 Comparison of methods 
 When quality control indicates any change in method. 
1.14.1.1The Objectives of the Validation  
 The primary objective of validation is to form a basis for written 
procedure for production and process control which are designed to assure that the drug 
products have the identity, quality and purity they purport or are represented to possess. 
i. Assurance of quantity. 
ii. Government regulation. 
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1.14.1.2 The Importance of Validation  
i. As the quality of product cannot always be assured by routine quality control 
because of testing of statistically insignificant number of sample, the validation 
thus should provide adequacy and reliability of a system or product to meet the 
pre-determined criteria or attributes providing high degree of confidence that the 
same level of quality is consistently built into each of finished product from batch 
to batch. 
ii. Retrospective validation is useful for trend comparison of results complains to 
cGMP to cGLP. 
iii. For taking appropriate action in case of non-compliance. 
1.14.1.3 The Benefits of Validation  
 Regulatory compliance 
 Minimize rejection and reworking 
 Minimize utility costs 
 Minimize complaints 
 Reduce testing requirements 
 More rapid and reliable start-up new equipment 
 Easier scale-up from development 
1.14.2 Types of Validation (Michael E. Swartz et al., 2009)   
        The validation is divided into different types. They are, 
Prospective Validation 
This method is employed when historical data of the product is not available or is 
not sufficient and in process and finished product testing is not adequate to ensure 
reproducibility or high degree of compliance to product likely attributes. 
Retrospective Validation 
 This provides trend of comparative result (i.e.) review and evaluation of existing 
information for comparison when historical data is sufficient and readily available. 
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Concurrent Validation 
Based on information generated during implementation of a system for this 
extensive testing and monitoring are performed as part of initial run of the method. 
Re-Validation 
 Revalidation provides the evidence that changes in a process and are the process 
environment, introduced either intentionally or unintentionally, do not adversely affect 
process characteristic and product quality.  
There are two basic categories of revalidation. Revalidation in case of known 
change (including transfer of process from one company to another or from one site to 
another). Periodic revalidation carried out at scheduled intervals. 
1.14.3 Reasons/Purpose of Validation: (Sethi, et al., 1996) 
 Setting standards of evaluation procedures. 
 Taking appropriate action in case of non-compliance. 
 Retrospective validation is useful for trend comparison of results compliance to 
cGMP/cGLP.                                                                                                                                       
 Closer interaction with pharmacopoeia forum to address analytical problems. 
Enables scientist to communicate scientifically and effectively on technical 
matters. 
1.14.4 Analytical Validation (Shah et al., 1991) 
 Analytical validation of a pharmaceutical product or of specific ingredients within 
the product is necessary to ensure its safety/efficacy throughout all phases of its shelf life. 
Such monitoring is in accordance with the specifications elaborated/validated during the 
product development. 
 Analytical method validation is the process to confirm that the analytical 
procedure employed for a specific test is suitable for its intended use. Method validation 
is the documented successful evaluation of an analytical method that provides a high 
level of assurance that such method will consistently yield result that are accurate with in 
previously established specification. 
 Analytical testing of a pharmaceutical product is necessary to ensure its purity, 
stability, safety and efficacy. Analytical method validation is an integral part of the 
quality control system.  
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 Although a thorough validation cannot rule out all potential problems, the process 
of method development and validation should address the most common ones. 
 Analytical method validation ensures that the selective analytical method will 
give reproducible and reliable results adequate for intended purpose. 
1.14.5 Analytical Parameters used in Assay Validation as per ICH Guidelines               
(Code Q2A; Q2B, ICH Guidelines 1994 and 1996; USP, 1995) 
The objective of validation of an analytical procedure is to demonstrate that it is suitable 
for its intended purpose. A tabular summation of the characteristics applicable to 
identification, control of impurities and assay procedures is included. 
Types of Analytical Procedures to be Validated 
 The discussion of the validation of analytical procedures is directed to the four 
most common types of analytical procedures, 
Identification Tests 
 Quantitative tests for impurities content. 
 Limit tests for the control of impurities. 
 Quantitative tests of the active moiety in samples of drug substance or drug 
product or other selected component(s) in the drug product. 
 A brief description of the types of tests considered in this document is provided 
below. 
 Identification tests are intended to ensure the identity of an analyte in a sample 
this is normally achieved by comparison of a property of the sample (example 
spectrum, chromatographic behaviour, chemical reactivity etc.) to that of a 
reference standard. 
Complete Method Development and Validation Parameters 
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Accuracy 
 The word accuracy refers to term trueness. It expresses the closeness between the 
true value or the reference value and the value found in the analysis. True value is the 
accepted value of the reference value. The accuracy is determined by the recovery 
studies. 
Precision 
 Precision expresses the degree of scatter between a series of measurement made 
in multiple sampling from the same homogenous sample. It may be considered fewer 
than three levels 
 Repeatability 
 Intermediate precision 
 Reproducibility 
The precision is expressed as Variance, standard deviation and coefficient of 
variation for a series of measurements. 
The repeatability is confirmed by a minimum of 6 estimations at 100% of test 
concentrations. The standard deviations should be less than 2. 
The intermediate precision is confirmed by inter day and intraday analysis, 
different instruments and different analyst.  
Specificity 
 Specificity refers to the ability of the method to assess the analyte in the presence 
of other components like impurities, matrix or degradants, etc. The implications of 
specificity are 
Identification: To ensure identity 
Purity tests: To determine the content of impurity 
Assay: Content of the analyte in the sample 
Limit of Detection 
 It is the lowest amount of an analyte that can be detected by the analytical 
procedure but cannot be quantified exactly. 
The LOD is performed based on the following parameters 
 Based on visual examination 
 Based on signal to noise ratio 
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 Based on the standard deviation and slope value. 
The visual examination is done by analysing the sample with known quantity of 
standard and by establishing the minimum level at which the analyte can be detected. 
A signal to noise ratio of 3 o 2.1 is considered as acceptable value for calculating 
the detection limit. 
Based on slope and standard deviation values, Detection limit can be calculated 
by using the formula, 
ܮܱܦ = 3.3ߪ
ܵ
 
Where, 
 σ = the standard deviation of the response 
S = the slope of the calibration curve (of the analyte) 
Limit of Quantitation 
 The lowest amount of the analyte which can be quantified by an analytical 
method with precision and accuracy is the limit of quantification. 
Three approaches are made for determining the quantification limit. They are similar to 
that of determining the detection limit.  
 Based on visual examination 
 Based on signal to noise ratio 
 Based on slope and standard deviation value 
ܮܱܳ = 10ߪ
ܵ
 
Where, 
 σ = the standard deviation of the response. 
 S = the slope of the calibration curve (of the analyte). 
Linearity 
 Linearity is the ability of an analytical method to obtain results which are directly 
proportional to the analyte concentration within a given range. The linearity is evaluated 
as a plot of signals as a function of analyte concentration. The statistical parameters such 
as the slope, intercept, regression equation and correlation coefficient are calculated. For 
establishing of linearity, a minimum of 5 concentrations is required. 
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Range 
 It is the interval between the lower and upper limit of concentration in a sample 
for which the analytical method has suitable precision, accuracy and linearity. The 
minimum range considered for the assay of drug or finished product is form 80 to 120 
percent of the test concentration. 
Robustness 
 It is the ability of an analytical method to remain unaltered by small but deliberate 
variations in various parameters of the method and indicate its reliability. The typical 
variation includes stability of analytical solutions and extraction time. In case of HPLC, 
the change in the ratio of mobile phase, flow rate, variation of pH of the solution are done 
for determining the robustness of the method. 
Acceptance criteria of validation 
S.No. Characteristics Acceptance Criteria 
1 Accuracy Recovery 98-102% with 80,100,120% spiked sample. 
2 Precision RSD < 2% 
2a Repeatability RSD < 2% 
2b Intermediate Precision RSD < 2% 
3 Specificity/ Selectivity No interference 
4 Detection Limit S/N > 2 or 3 
5 Quantification  Limit S/N > 10 
6 Linearity r > 0.999 
7 Range 80-120% 
 
1.15 BASIC STATISTICAL PARAMETERS  
 (Gupta, et al., 1995; Bolton, et al.,2004; Mendham, et al., 1994)   
 Statistical techniques have been widely used in many diverse areas of scientific 
investigation. Statistical applications have been recognized as crucial to quality control 
procedure, test, specification and definitions. Principle of modern analytical techniques 
and skill in their application are necessary attribute of the successful pharmaceutical 
analyst, thus does not ensure the satisfactory solution of all the problem that may 
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encountered. Some auxiliary knowledge methods those can aid the analyst in designing 
experiment, collecting data, and interpreting the result. 
1.15.1 Linear Regression 
 Linear regression is a statistical technique that defines the functional relationship 
between two variables by best-fitting straight line.  Once a linear relationship has been 
shown to have a high probability by the value of the correlation coefficient ‘r’, then the 
best straight line through the data points has to be estimated. This can often be done be 
done by visual inspection of the calibration graph, but in many cases it is far more 
sensible to evaluate the best straight line by linear regression (the method of least 
squares). 
The equation of straight line is  
y = mx + c 
Where, y the dependent variable is plotted as result of changing x, the independent 
variable. 
         To obtain the regression line ‘y on x’ the slope ‘m’ of the line and the intercept ‘c’ 
on the y axis are given by the following equation. 
m = ୒ ∑୶୷ି(∑୶) (∑୷) 
୒∑୶మି (∑୶)మ         and      c = (∑୷) ൫∑ ୶మ൯ି (∑୶)(∑୶୷)୒ ∑୶మି (∑୶)మ  
1.15.2 Correlation Coefficient (r) 
         It is a procedure commonly used to characterize quantitatively the relationship 
between variable. Correlation is related to linear regression.  To establish whether there is 
a linear relationship between two variables x1 and y1, use Pearson’s correlation 
coefficient r. r = n∑ xଵ yଵ −  ∑ xଵ yଵ{[݊∑ݔଵଶ − (∑ݔଵ)ଶ] [݊∑ݕଵଶ − (∑ݕଵ)ଶ]}ଵ ଶൗ  
  Where n is the number of data points. 
 The value of r must lie between +1 and -1, the nearer it is to +1, the greater the 
probability that a definite linear relationship exists between the variables x and y, values 
close to +1 indicate positive correlation and values close to -1 indicate negative 
41 
 
correlation values of ‘r’ that tend towards zero indicate that x and y are not linearly 
related (they made be related in a non-linear fashion). 
1.15.3 Standard Deviation (SD) 
          It is commonly used in statistics as a measure of precision statistics as a measure of 
precision and is more meaningful than is the average deviation. It may be thought of as a 
root-mean-square deviation of values from their average and is expressed mathematically 
as 
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Where, 
S is standard deviation. 
If N is large (50 or more) then of course it is immaterial whether the term in the 
denomination is N -1 or N  
Σ       = sum 
x       = Mean or arithmetic average. 
x -x  = deviation of a value from the mean. 
N      = Number of observations. 
1.15.4 Percentage Relative Standard Deviation (%RSD) 
 It is also known as coefficient of variation (CV). It is defined as the standard 
deviation (SD) expressed as the percentage of mean. 
                                         C 100
x
S.DRSD  %or  V 
 
          Where,  
SD   = the standard deviation, 
x       = Mean or arithmetic average. 
 The variance is defined as S2 and is more important in statistics than S itself.  
However, the latter is much more commonly used with chemical data. 
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1.15.5 Standard Error of Mean (SE) 
 Standard error of mean can be defined as the value obtained by division of 
standard deviation by square root of number of observations. It is mathematically 
expressed as  
n
S.D.S.E.   
   Where, 
            SD = Standard deviation. 
                           n = number of observation 
1.15.6 Confidence Interval (CI) 
 A confidence interval gives an estimated range of values which is likely to 
include a unknown population parameter, the estimated range being calculated from a 
given set of sample data. A confidence interval with a particular confidence level (95% 
selected by the user) is intended to give the assurance that, if the statistical model is 
correct then the interval could deliver the true value. 
Confidence interval for a normal population, 
   
Where  
     = Sample mean 
            = upper  critical value of standard normal distribution 
    N = Size of sample  
    σ = Standard deviation 
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2. LITERATURE REVIEW 
2.1 DRUG PROFILE 
2.1.1 Atorvastatin Calcium 
  
(IP, 2007; The Merck index, 2006; Martindale, The Extra Pharmacopeia, 1993; Clarke’s, 
2004; Rang & Dale et al.,2008; www.drugs.com/atorvastatin.html) 
 
Molecular Structure 
                         
N
O
+
F
O
O
-
OH
Ca2
+
2
 
Chemical Name 
 (βR,8R)-2-(4-fluorophenyl)-α,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-
(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid trihydrate. 
 
Molecular Formulae 
 C66H68CaF2N4O10.3H20 
 
Molecular Weight  
 1155.36 g/ mol 
 
Category 
 Antilipemic 
 
Description 
 A white to off-white, crystalline powder. 
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Solubility 
  Freely soluble in methanol; slightly soluble in ethanol; very slightly soluble in 
acetonitrile; distilled water, phosphate buffer pH 7.4; insoluble in aqueous solution of   
pH 4 and below. 
 
Identification 
1. Melting Point 
Standard Value Observed Value* 
159.2º - 160.7ºC 160.ºC 
(*Average of six observations) 
2. IR spectrum was recorded and shown in figure.1 
 
Storage 
 Stored protected from light at a temperature not exceeding 30ºC. 
 
pKa value 
 4.46 
 
Mechanism of Action 
 Atorvastatin Calcium a synthetic cholesterol-lowering agent, is a medicine called 
as HMG-CoA (3hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitor. These 
enzymes are involved in cholesterol biosynthesis by catalyzing the conversion reaction of 
HMG-CoA to mevalonate. The function of lowering the amount of cholesterol leads to 
the result in clearing the LDP (low-density lipoprotein) cholesterol in the blood by 
increased LDL receptors. The Calcium salt of Atorvastatin is used in the treatment of 
primary hypercholesterolemia and dyslipidemia.  
Pharmacokinetics 
Absorbtion 
 Rapidly absorbed; Tmax is 1 to 2 h. Bioavailability is approximately 14%; low 
bioavailability is because of pre systemic C1 in G1 mucosa and/or hepatic first-pass 
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metabolism. Food decreases rate and extent of absorbtion approximately 25% and 9% 
respectively, but does not alter efficacy. 
Distribution 
 98% bind to plasma protein albumin. 
Metabolism 
 Hepatic and extra hepatic metabolism, including first- pass metabolism and 
CYP3A4. 
Elimination 
 Eliminated primarily in bile. Less than 2% of dose is recovered in the urine. 
Plasma t1/2 is approximately 14 h. 
 
Adverse Effects 
 Atorvastatin Calcium are well tolerated: mild unwanted effects include 
gastrointestinal disturbance, increased plasma concentration of liver enzymes, insomnia 
and rash. More serious adverse effects are rare but include severe myositis 
(“rhabdomyolysis”) and angio edema.  
 
Drug Interactions 
The risk of myopathy during treatment with statins is increased with concurrent 
administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or 
strong CYP 3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and 
itraconazole). 
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2.1.2 Aspirin 
 
(IP, 2007; USP, 2009; BP 2009; The Merck index, 2006; Martindale, The Extra 
Pharmacopeia, 1993; Clarke’s, 2004; Rang & Dale et al.,2008) 
 Molecular Structure 
                       
CO 2H
O
CH3O  
Chemical Name 
 2-(Acetyloxy)benzoic acid. 
 
Molecular Formulae 
 C9H8O4 
 
Molecular Weight 
 180.2 g/ mol 
 
Category 
 Analgesic; anti pyretic; anti-inflammatory; anti-thrombotic 
 
Description 
 Colorless or white crystals, white crystalline powder; odorless or almost 
odourless. 
 
Solubility 
 Slightly soluble in water; freely soluble in alcohol; soluble in chloroform and 
ether. 
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Identification 
1. Melting Point 
 
 
 
(* Average of six observations) 
2. IR spectrum was recorded and shown in figure.4 
 
Storage 
 Stored protected from moisture at a temperature not exceeding 30ºC. 
 
pKa value 
 3.5 
 
Mechanism of Action 
 Aspirin acetylates prostaglandin endoperoxide synthase (prostaglandin G/H-
synthase) and irreversibly inhibits its cyclooxygenase (COX) activity. The enzyme 
catalyses the conversion of arachidonic acid to PGH2. Two isoforms of prostaglandin 
endo-peroxide synthase exist, PGHS-1 and PGHS-2. PGHS-1 is expressed consecutively 
in most cell types, including platlets. PGHS-2 is undetectable in most Malian cells but its 
expression can be induced rapidly in response to mitogenic and inflammatory stimuli. 
Pharmacokinetics 
Absorbtion 
 Rapidly and completely absorbed with systemic bioavailability of 80-100% in 
oral dosage form. 
Distribution  
  99.6% bind to plasma protein albumin. 
Metabolism 
Metabolized consider hepatic half life 300–650 mg dose: 3.1–3.2 h 
1 g dose: 5 h and 2 g dose: 9 h. 
 
Standard Value Observed Value* 
135ºC 139ºC 
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Elimination 
95% was eliminated through kidneys. 
 
Adverse Effects 
Therapeutic doses: some gastric bleeding usually minimal, is common 
Large doses: Dizziness, deafness and tinnitus 
Toxic doses: Uncompensated respiratory acidosis plus metabolic acidosis, the 
later seen particularly in children 
Aspirin is epidemiologically linked with an encephalitis (Reye’s syndrome) if 
give to children with viral infections. 
 
Drug Interactions 
Aspirin given concomitantly with warfarin, aspirin can cause a potentially 
hazardous increase in the risk of bleeding, digoxin, clonidine etc. 
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2.1.3 Ramipril 
 
(IP, 2007; USP, 2009; BP 2009; The Merck index, 2006; Martindale, The Extra 
Pharmacopeia, 1993; Clarke’s, 2004; www.drugs.com/ramipril.html) 
 Molecular Structure 
                                  
O
O
CH3
NH
CH3
N
H
H
O
OH
O
 
Chemical Name 
(2S.3aS.6aS)-1-[(S)-N-[(S)-1-Carboxy-3-phenylpropyl]alanyl] octahydrocyclopenta[b]pyrrole-2-
carboxylic acid. 1-ethyl ester. 
Molecular Formulae 
 C23H32N2O5  
Molecular Weight 
 416.5 g/ mol 
Category 
 Anti-hypertensive 
Description 
 White or almost white, crystalline powder. 
Solubility 
 Sparingly soluble in water, freely soluble in methanol. 
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Identification  
1. Melting Point 
Standard Value Observed Value* 
106º - 108ºC 108.16ºC 
      (*Average of six observations) 
2. IR spectrum was recorded and shown in figure.2 
Storage 
 Stored at protected from moisture. 
pKa value 
 3.32 
Mechanism of Action 
 Ramipril, the active metabolite, competes with angiotensin I for binding at the 
angiotensin-converting enzyme; block the conversion of angiotensin I to angiotensin II. 
As angiotensin II is a vasoconstrictor and a negative-feedback mediator for rennin 
activity, lower concentrations result in a decrease in blood pressure and an increase in 
plasma renin. Ramipril may also act on kinase II, an enzyme identical to ACE that 
degrades the vasodilator bradykinin. 
Pharmacokinetics 
Absorption 
 Well absorbed with systemic bioavailability of 90%. 
Distribution 
 99% binds to plasma protein albumin. 
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Metabolism 
 Metabolized to a carboxylic acid derivative by cytochrome P450. 
Elimination  
 Excreted unchanged and as active metabolite in urine. 
Adverse Effects 
 Chronic cough (due to increase the bradykinin level) 
 Dizziness 
 Pedal edema 
Drug Interactions 
 Digoxin, penicillin and cyclosporine, etc. 
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2.1.4 Metoprolol Tartrate 
 
(IP, 2007; BP 2009; The Merck index, 2006; Martindale, The Extra Pharmacopeia, 1993; 
Clarke’s, 2004) 
Molecular Structure 
                   CH2CH2OCH3
NH CH3
CH3
OH
OHOH
OHOH
COOH
COOH
 
Chemical Name 
 (RS)-1-(isopropylamino)-3-p-(2-methoxyethyl)phenoxypropan-2-ol (2R,3R)-
tartrate 
Molecular Formulae 
 (C15H25NO3)2,C4H6O6 
Molecular Weight 
 684.8 g/mol 
Category 
 Anti hypertensive; anti angina; anti arrhythmic. 
Description 
 A white, crystalline powder or colorless crystals. 
 
 
53 
 
 Solubility 
Very soluble in water, soluble in ethanol and chloroform; practically insoluble in 
ether. 
Identification 
1. Melting Point 
 
                   (*Average of six observations) 
2. IR spectrum was recorded and shown in figure.3 
Storage 
 Stored protected from light 
pKa value 
 9.7 
Mechanism of Action 
 Metoprolol is a competitive β1-selective beta blocker; it blocks β1 receptors at 
dosages that are much lower than those necessary to block β2 receptors in heart and 
vascular smooth muscles.  
Pharmacokinetics 
Absorption 
Well absorbed with the systemic bioavailability of 50% its increasing while 
continue the dose and intake with food. 
Standard Value Observed Value* 
120º - 121ºC 120ºC 
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Distribution 
 12% is bound to human serum albumin and 5-10% is bind to plasma proteins. 
Metabolism 
 Metoprolol is extensively metabolized by the cytochrome P450 enzyme system in 
the liver. 
Elimination 
 95% of the oral dose was eliminated through urine and 5% of the dose unmodified 
via kidneys. 
Adverse Effects 
 Hypotension 
 Myocardial infraction 
 Dizziness 
 Mask the glucose level in diabetic patients 
Drug Interactions 
 Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when 
given with beta-blocking agents. Patients treated with Metoprolol Tartrate plus a 
catecholamine depletor should therefore be closely observed for evidence of hypotension 
or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 
Both digitalis glycosides and beta blockers slow atrioventricular conduction and 
decrease heart rate. Concomitant use can increase the risk of bradycardia. General 
anesthetics, clonidine, digoxin, and CYP2D6 inhibitors. 
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2.2 REPORTED METHODS 
1. Satheesh  Kumar  Shetty et al., (2011), reported “Stress Degradation Behavior of a 
Polypill and Development of Stability Indicating UHPLC Method for the 
Simultaneous Estimation of Aspirin, Atorvastatin, Ramipril and Metoprolol 
Succinate”. The chromatographic Separations were achieved on a Waters Acquity UPLC 
BEH C18 column 100×2.1mm, 1.7µm stationary phase with simple mobile phase 
combination buffer consisting of 0.1% Perchloric acid (pH 2.5) and Acetonitrile in the 
ratio of 80:20% v/v, delivered in a gradient mode and quantification was carried out 
using ultraviolet detection at 215 nm with a flow rate of 0.6 ml/ min. 
2. Kamatchi Sankar A.S. et al., (2011), reported “Simultaneous Estimation of 
Ramipril, Acetyl salicylic acid and Atorvastatin Calcium by Chemometrics Assisted 
UV-Spectrophotometric Method in Capsules”. The three different spectrophotometric 
methods for simultaneous estimation of Ramipril, Aspirin and Atorvastatin Calcium in 
raw material and in formulations are described. Overlapped data was quantitatively 
resolved by using chemometric methods viz. Inverse Least square (ILS), Principal 
Component Regression (PCR) and Partial Least Square (PLS). Calibration was 
constructed using the absorption data matrix corresponding to the concentration data 
matrix. The linearity range was found to be 1-5, 10-50 and 2-10 µg/ ml for Ramipril, 
Aspirin and Atorvastatin Calcium, respectively. 
3.  Shaik Harun Rasheed et al., (2010), reported “A Stability-Indicating LC Method for 
the Simultaneous Determination of Metoprolol, Atorvastatin and Ramipril in 
Combined Pharmaceutical Dosage Form”. A chromatographic separation of the three 
drugs was achieved with a Hypersil C8,15-cm analytical column using buffer-acetonitrile 
(55:45 v/v). The buffer used in mobile phase contains 0.02 M Sodium perchlorate in 
double distilled water. The instrumental settings are flow rate of 1.0 ml/ min, column 
temperature at ambient, the detector wavelength of 210 nm for Metoprolol, Atorvastatin 
and Ramipril using an ultra violet detection. 
 4. Raja Kumar Seshadri et al., (2010), reported “Simultaneous Quantitative 
Determination of Metoprolol, Atorvastatin and Ramipril in Capsules by a Validated 
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Stability-Indicating RP-UPLC Method”. The method was developed using Zobrax® 
XDB-C18 (4.6 mm × 50 mm, 1.8 µm) column with a mobile phase consisting of 0.06% 
ortho phosphoric acid in milli Q® water having an ion pair reagent, 0.0045 sodium lauryl 
sulphate as buffer, at ratio of buffer: Acetonitrile (50:50 v/v), at 55ºC column temperature 
with the flow rate of 1.0 ml/ min, ultra violet detection at 210 nm. The retention times 
were about 1.3, 2.1 and 2.6 min for Metoprolol, Atorvastatin and Ramipril, respectively. 
 5. Patole S.M. et al., (2010), reported “A Validated HPLC Method for Analysis of 
Atorvastatin Calcium, Ramipril and Aspirin as the Bulk Drug and in Combined 
Capsule Dosage Forms”. The separation was carried out on C18 column using methanol 
and acetate buffer (pH 3.1) adjusted with diluted ortho phosphoric acid in the ratio of 
70:30 v/v.  The detection wavelengths were 210 nm for Ramipril, 245 nm for 
Atorvastatin Calcium and 254 nm for Aspirin, with the flow rate of 1.0 ml/ min. The 
retention time of Atorvastatin Calcium was 8.38±0.10 min, Ramipril was 5.62±0.02 min 
and Aspirin was 3.04±0.15 min. 
6. Vijaya Kumar Ravi et al., (2008), reported “LC and LC-MS Methods for the 
Investigations of Polypills for the Treatment of Cardiovascular Diseases:             
part 1 Separation of Active Components and Classification of their 
Interaction/Degradation Products”. Chromatographic was carried out on C8 column 
using acetonitrile and phosphate buffer (pH 2.3) as mobile phase in the ratio of 70:30 v/v, 
with the flow rate of 1.0 ml/ min at 210 nm.  
7.  Londhe S.V. et al., (2011), reported “ Development and Validation of RP-HPLC 
for Simultaneous Determination of Aspirin, Atorvastatin Calcium and Clopidogrel 
Bisulphate in Capsules”. The chromatographic separation was carried out on an Intersil 
ODS analytical column (150×4.6 mm; 5 μm) with a mixture of acetonitrile:phosphate 
buffer pH 3.0 adjusted with ortho phosphoric acid (50:50, v/v) as mobile phase; at a flow 
rate of 1.2 ml/ min. UV detection was performed at 235 nm. The retention times were 
1.89, 6.6 and 19.8 min. for aspirin, Atorvastatin Calcium and clopidogrel bisulphate, 
respectively. 
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8. Ismail et al., (2008), reported “RP-HPLC Method for the Simultaneous 
Determination of Aspirin, Atorvastatin Calcium and Pioglitazone in Capsule Dosage 
Form”. The separation was carried out on Zorbax SBCN, 5μm, 4.6 x 250mm, AGILENT 
column was used for the separation of these compounds. Acetonitrile and phosphate 
buffer with pH 3.5 (40 %: 60 % v/v) is used as the mobile phase, with the flow rate of     
1 ml/ min, 261nm was the detection wavelength for this study. 
9. Yogesh B. Zambare et al., (2009), reported “Simultaneous Estimation of 
Atorvastatin and Ramipril by First Order Derivative Spectrophotometric Method”. 
The first order derivative spectrophotometric method was developed using methanol as 
solvent. The wavelengths selected for the analysis were 246 nm and 208 nm for 
Atorvastatin Calcium and Ramipril, respectively. Beer’s law obeyed the concentration 
range of 10 – 50 g/ ml for both the drugs. 
10. GARG Gopal  et al., (2007), reported “Simultaneous Estimation of Ramipril and 
Metoprolol Tartrate in Combined Dosage Forms”.  In simultaneous equation method, 
the drugs were determined by using the absorbance values of Ramipril and Metoprolol at 
selected wavelengths, viz. 205 nm and 222.5 nm respectively. The second method 
depends on the application of area under the curve at selected wavelength range, 200 to 
210 nm and 217.5 to 227.5 nm for Ramipril and Metoprolol tartrate, respectively. Third 
method is based on the determination of graphical absorbance ratio at two selected 
wavelengths; one being the iso-absorptive point for the drugs (216.5 nm) and the other 
being the absorption maximum of Metoprolol (222.5 nm). The fourth method is based on 
the derivative spectrophotometric method at zero crossing wavelengths. 
11. Nagaraj et al., (2007), reported “Simultaneous Quantitative Resolution of 
Atorvastatin Calcium and Fenofibrate in Pharmaceutical Preparation by using 
Derivative Ratio Spectrophotometry and Chemometric Calibrations”. In ratio 
spectra derivative spectrophotometry, analytical signals were measured at wavelengths 
corresponding to either maximums or minimums for both drugs in first derivative spectra 
of ratio spectra obtained by using either spectrum as divisor. For the remaining four 
methods using chemometric techniques, namely, classical least squares (CLS), inverse 
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least squares (ILS), principal component regression (PCR) and partial least squares 
(PLS), the calibrations were constructed by using the absorption data matrix 
corresponding to the concentration data matrix, with measurements in the range of       
231 - 310 nm (Deltalambda = 1 nm) in their zero-order spectra. 
12. Khan M.R. et al., (2006), reported “Simultaneous Spectrophotometric 
Determination of Atorvastatin Calcium and Amlodipine Besylate in Tablets”. First 
method employs formation and solving of simultaneous equations using 245 nm and   
363 nm as two analytical wavelengths. Second is dual wavelength method, which uses 
the difference of absorbance value at 259.9 nm and 354 nm for estimation of Atorvastatin 
Calcium and absorbance at 363 nm for Amlodipine besylate. Fifty percent methanol was 
used as solvent. 
13. Sonawane S.S. et al., (2007), reported “Simultaneous Spectrophotometric 
Estimation of Atorvastatin Calcium and Ezetimibe in Tablets”. The method involves, 
Q- absorbance ratio method, the absorbance measurement at 235.5 nm (iso-absorptive 
point) and 246.0 nm (λmax of Atorvastatin Calcium), in methanol. 
 
14.  Popat B. Mohite et al., (2010), reported “Simultaneous Estimation of Ramipril 
and Telmisartan in Tablet Dosage Form by Spectrophotometry”. The method based 
on UVspectrophotometric determination of two drugs, Method A is by using 
multicomponent method. It involves absorbance measurement at 205.0 nm (λmax of 
Ramipril) and 291.0 nm (λmax of Telmisartan) in 0.2M H2SO4. Beer’s law obeyed in the 
concentration range of 5-40 μg/ ml for Ramipril and 2-20 μg/ ml for Telmisartan.  
Method B was graphical absorbance method which is based on measurement of 
absorbance of Ramipril and Telmisartan at 222.0 nm (iso-absorptive point of Ramipril 
and Telmisartan) and 291.0 nm (λmax of Telmisartan). 
15. Priyanka R. Patil et al., (2009), reported “Simultaneous Estimation of Ramipril 
and Amlodipine by UV-Spectrophotometric Method”. The method involved the 
estimation of Ramipril and Ambroxol by simultaneous equation method. The 
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wavelengths selected for the analysis are 210 nm λmax of Ramipril and 238 nm λmax of 
Ambroxol. The solvent used was methanol. 
16. Gupta K.R. et al., (2008), reported “New Spectrophotometric Method for 
Simultaneous Determination of Metoprolol Tartrate and Hydrochlorthiazide in 
Tablets”. The two-wavelength method for simultaneous determination of Metoprolol and 
Hydrochlorothiazide in fixed dose combination tablet. The wavelengths selected for 
method were 257.8 nm, 282.9 nm and 315.0 nm. The absorbance difference at first two 
wavelengths was used for determination of Metoprolol and the latter was used for 
determination of Hydrochlorthiazide. 
17. Lincy Joseph et al., (2008), reported “Simultaneous Estimation of Atorvastatin 
and Ramipril by RP-HPLC and Spectroscopy”. Separation was done by Intersil ODS 
column (250 × 4.6 mm) 5 at 40ºC using 50% acetonitrile and 50% Sodium perchlorate 
buffer pH 2.5 with dilute phosphoric acid as mobile phase. With the flow rate was   
1.2ml/ min at 215 nm. The simultaneous equation method has selected two wavelengths 
247 nm and 208 nm the λmax of Atorvastatin Calcium and Ramipril, respectively. 
18. Chandra Bose R.J. et al., (2011), reported “Validated RP-HPLC Method for the 
Simultaneous Estimation of Ramipril and Metoprolol Tartrate in Bulk and Tablet 
Dosage Form”. The separation was achieved on a Hypersil C18, 150 mm x 4.6 mm, 5 μm 
particle size in isocratic mode with mobile phase acetonitrile: methanol: 10mM Acetate 
buffer (30: 50: 20 v/v/v) and pH adjusted to 5 ± 0.1 with triethanolamine was used. The 
flow rate was 1.0 ml/ min and absorbance of individual component was measured at    
210 nm. The retention times of Metoprolol tartrate and Ramipril were found to be       
2.85 and 3.88 min, respectively. 
19. Shah D.A. et al., (2004), reported “Development and Validation of a RP-HPLC 
Method for Determination Atorvastatin Calcium and Aspirin in a Capsule Dosage 
Form”. The separation was achieved on a A Phenomenex Gemini C18, 5 mm column 
having 250 x 4.6 mm i.d. in isocratic mode, with mobile phase containing                    
0.02 M potassium di hydrogen phosphate: methanol (20:80) adjusted to pH 4 using                                     
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ortho phosphoric acid was used. The flow rate was 1.0 ml/ min and effluents were 
monitored at 240 nm. The retention times of Atorvastatin Calcium and Aspirin were      
5.4 min and 3.4 min, respectively. 
20. Shah D.A. et al., (2008), reported “Stability Indicating RP-HPLC Estimation of 
Atorvastatin Calcium and Amlodipine Besylate in Pharmaceutical Formulations”. 
The separation was carried out on a Phenomenex Gemini C18, 5 μm column having 
250×4.6 mm i.d. in isocratic mode, with mobile phase containing 0.02 M potassium 
dihydrogen phosphate:acetonitrile:methanol (30:10:60, v/v/v) adjusted to pH 4 using 
ortho phosphoric acid was used. The flow rate was 1.0 ml/ min and effluents were 
monitored at 240 nm. The retention times of Atorvastatin Calcium and Amlodipine 
besylate were 11.6 min and 4.5 min, respectively. 
21. Jain N. et al., (2008), reported “Development and Validation of RP-HPLC Method 
for Simultaneous Estimation of Atorvastatin Calcium and Fenofibrate in Tablet 
Dosage Forms”. The separation was achieved by Luna C18 column and methanol:   
acetate buffer pH 3.7 (82:18 v/v) as mobile phase, at a flow rate of 1.5 ml/ min. Detection 
was carried out at 248 nm. Retention times of Atorvastatin Calcium and Fenofibrate was 
found to be 3.02+0.1 and 9.05+0.2 min, respectively. 
22. Srinivasa Rao K. et al., (2010), reported “RP-HPLC Method for the Determination 
of Losartan Potassium and Ramipril in Combined Dosage Form”. The separation 
was achieved by Hypersil ODS C18, 4.6×250 mm, 5 μm column in isocratic mode, with 
mobile phase acetonitrile:methanol:10 mM tetra butyl ammonium hydrogen sulphate in 
water in the ratio of 30:30:40% v/v/v was used. The flow rate was 1.0 ml/ min and 
effluent was monitored at 210 nm. The retention times of Losartan Potassium and 
Ramipril were 4.7 and 3.3 min, respectively. 
23. Kurade V.P. et al., (2009), reported “RP-HPLC Estimation of Ramipril and 
Telmisartan in Tablets”. The separation was achieved by Genesis C18 column having 
dimensions of 4.6×250 mm and particle size of 5 μm in isocratic mode, with mobile 
phase containing a mixture of 0.01 M potassium dihydrogen phosphate buffer (adjusted 
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to pH 3.4 using ortho phosphoric acid): methanol : acetonitrile (15:15:70 v/v/v) was used. 
The mobile phase was pumped at a flow rate of 1.0 ml/ min and the eluents were 
monitored at 210 nm. The selected chromatographic conditions were found to effectively 
separate Ramipril (Rt: 3.68 min) and Telmisartan (Rt: 4.98 min) having a resolution of 
3.84.   
24. Rawool N.D. et al., (2011), reported “Analytical Method for the Simultaneous 
Estimation of Metoprolol Tartrate and Hydrochlorthiazide using RP-HPLC”. The 
separation is done on a C18 column using phosphate buffer along with methanol as mobile 
phase, in the proportion of 60:40 and it is estimated at a λmax of 226 nm with a flow rate 
of  1 ml/ min. 
25. Sohan S. Chitlange  et al., (2008), reported “RP-HPLC Method for Simultaneous 
Estimation of Metoprolol Tartrate And Amlodipine Besylate in Tablet 
Formulation”. The determination was carried out on a Kromasil C18 (250 x 4.6 mm, 5 
µm) column using a mobile phase of 0.02 M phosphate buffer solution: acetonitrile 
(70:30v/v, pH 3.0). The flow rate was 1.0ml/ min with detection at 221 nm. The retention 
time for Amlodipine was 2.57 min and for Metoprolol 4.49 min. 
26. Sagar S. Panda et al., (2010), reported “Ion-Pairing RP-HPLC Method for 
Simultaneous Determination of Aspirin and Clopidogrel Bisulphate in Tablet and 
Capsule Dosage Form”. The proposed RP-HPLC method utilized LiChroCART-
LiChrospher 100;C18 column (250mm × 4mm i.d.,5μm) and mobile phase consisting of 
acetonitrile:0.01M TBAHS (50:50% v/v) at a flow rate of 1.0ml/ min. Quantification was 
achieved with UV detection at 240 nm. The retention times were 3.167min and 5.758min 
for Aspirin and Clopidogrel, respectively. 
27. Swapnil D. Jadhav et al., (2010), reported “Spectrophotometric Methods for 
Estimation of Atorvastatin Calcium from Tablet Dosage Forms”. In the present 
incestigation, hydrotropic solubilization is employed to enhance the aqueous solubilities 
of poorly water- soluble drugs like Atorvastatin Calcium in tablet dosage forms. This 
method utilizes 2.0 M urea solution as, hydrotropic solubilizing agent. In the urea 
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solution Atorvastatin Calcium shows maximum absorbance at 240 nm. The 2.0 M urea 
solution does not show any interference with the sampling wavelength. Another method 
is formation of green color complex between the drug Atorvastatin Calcium and 0.3 % 
w/v ferric chloride and 0.02 % w/v potassium ferricyanide. The green colored complex 
shows the maximum absorbance at 787 nm. 
 28. Anil kumar Sharma et al., (2010), reported “Simultaneous Estimation of 
Atorvastatin Calcium, Ramipril and Aspirin in Capsule Dosage Form using 
HPTLC”. The method was developed using precoated silica gel 60F254 as stationary 
phase. The mobile phase used was a mixture of benzene: ethyl acetate: toluene: methanol: 
glacial acetic acid (4.0:4.5:1.0:0.5:0.1 v/v/v/v/v). Detection was carried out with ultra-
violet detection at 220 nm. The Rf values were about 0.45±0.02, 0.28±0.01 and 
0.72±0.02 for Atorvastatin Calcium, Ramipril and Aspirin, respectively. 
29. Nagavalli D. et al., (2010), reported “Simultaneous Estimation of Atorvastatin 
Calcium, Ezetimibe and Fenofibrate in Pure and in Combined Dosage Form by      
RP-HPLC and HPTLC Methods”. In method A, Atorvastatin Calcium, Ezetimibe and 
Fenofibrate were chromatographed on Phenomenax Luna ODS analytical column       
(150 mm x 4.6 mm i.d, 5) using Methanol: Acetonitrile: Water (50:30:20 v/v/v) as the 
mobile phase and scanned at 254 nm. Rt values of Atorvastatin Calcium, Ezetimibe and 
Fenofibrate were found to be 1.77 ± 0.02, 2.62 ± 0.01 and 9.26 ± 0.03 respectively.  In 
method B, Atorvastatin Calcium, Ezetimibe and Fenofibrate were chromatographed on 
silica gel 60 F254 TLC plate using chloroform: Toluene: Methanol: Glacial acetic acid 
(6:3:1:0.5 v/v/v/v) as the mobile phase and scanned at 254 nm.  The Rf value 
Atorvastatin Calcium, Ezetimibe and Fenofibrate were found to be 0.48 ± 0.02,           
0.56 ± 0.03 and 0.87 ± 0.02 respectively. 
30. Stephan Rathinaraj B. et al., (2010), reported “Determination of Atorvastatin 
Calcium and Ezetimibe by using HPTLC Method”. The stationary phase used was 
precoated silica gel 60F 254. The mobile phase used was a mixture of benzene, methanol, 
acetone and triethylamine (7:2:1:0.2 v/v/v/v). The detection spots were carried out at   
266 nm. 
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31. Gaikwad A.V. et al., (2011), reported “Simultaneous Estimation of Ramipril and 
Valsartan in Tablets by HPTLC”. Identification and determination were performed on 
10 cm × 10 cm aluminum-backed TLC plates, coated with 0.2 mm layers of               
silica gel 60 F254, previously washed with methanol using ethyl acetate : chloroform: 
glacial acetic acid, (8:2:0.2, v/v) as mobile phase. Detection was carried out 
densitometrically using UV detector at 220 nm. The Rf values were 0.15 for Ramipril and 
0.49 for Valsartan. 
 
32. Jitendra A. Wayadande et al., (2011), reported “Validated HPTLC Method for 
Simultaneous Estimation of Ramipril and Metazolone in Bulk Drugs and 
Formulation”. Chromatographic separation of the drugs was performed on aluminum 
plates precoated with silica gel 60 F254 as the stationary phase and the solvent system 
consisted of toluene : ethyl acetate : methanol : glacial acetic acid (4 : 4 : 1 : 0.2 v/v/v/v). 
Densitometric evaluation of the separated zones was performed at 223 nm. The two drugs 
were satisfactorily resolved with RF values 0.33 ± 0.02 and 0.59 ±0.02 for Ramipril and 
Metolazone respectively. 
 
33. Prajakta S. Nawale  et al., (2012), reported “Normal and RP-HPTLC Methods for 
Simultaneous Estimation of Telmisartan and Metoprolol Succinate in 
Pharmaceutical Formulation”. Method I was developed with aluminium plates 
precoated with silica gel 60F254S, and toluene : propanol : methanol : triethylamine      
(8 : 1 : 1 : 0.5 v/v) was used as as mobile phase. Method II was carried out using 
aluminium coated with RP-18 silica gel 60 F254S HPTLC plates using methanol : water : 
triethylamine (6 : 4 : 0.5 v/v) as mobile phase. Both analyses were scanned with a 
densitometer at 242 nm. In Method I, good separation and resolution of drugs were 
achieved with Rf values 0.45 ± 0.02 (Telmisartan) and 0.70 ± 0.02 (Metoprolol), while in 
Method II, Telmisartan and Metoprolol showed Rf values 0.55 ± 0.02 and 0.41 ± 0.02, 
respectively. 
34. Savitha S. Yadhav et al., (2005), reported “A Simple and Sensitive HPTLC Method 
for the Determination of Content Uniformity of Atorvastatin Calcium Tablets”. The 
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stationary phase was precoated silica gel 60 F254. The mobile phase used was a mixture 
of benzene: methanol (7:3 v/v). Combination of benzene: methanol offered optimum 
migration (Rf = 0.46±0.02). Detection of the spot was carried out at 281nm. 
35. Nageswara Roa Pilli et al., (2011), reported “Simultaneous Determination of 
Atorvastatin Calcium, Amlodipine Besylate, Ramipril and Benazepril in Human 
Plasma by LC-MS/MS and its Application to a Human Pharmakinetic Study”. The 
API-4000 LC-MS/MS was operated under the multiple-reaction monitoring mode using 
electrospray ionization. The Analytes and IS were extracted from plasma by simple 
liquid–liquid extraction technique using ethyl acetate. The reconstituted samples were 
chromatographed on C18 column by pumping 0.1% formic acid–acetonitrile (15:85, v/v) 
at a flow rate of 1 ml/ min. 
36. Gowda K.V. et al., (2007), reported “Liquid Chromatography Tandem Mass 
Spectrometry Method for Simultaneous Determination of Metoprolol Tartrate, 
Ramipril in Human Plasma”. The chromatographic separation was performed on a 
reversed-phase C8 column with a mobile phase of 10 mM ammonium formate-methanol 
(3:97, v/v). The protonated analyte was quantitated in positive ionization by multiple 
reactions monitoring with a mass spectrometer. 
37. Altuntas T.G., et al., (2004), reported “Liquid Chromatographic Determination of 
Atorvastatin in Bulk Drug, Tablets and Human Plasma” A simple, specific, and 
accurate high performance liquid chromatographic (HPLC) method for determination of 
atorvastatin in bulk drug, tablets, and human plasma have been developed. Liquid 
chromatography was performed on a RP‐Supelcosil C18 (5 µm, 150 × 4.6 mm) column 
and the mobile phase consisted of an acetonitrile:methanol:water (45:45:10 v/v/v), and a 
flow rate of 1.0 mL/min. The effluent was monitored on a UV detector at 240 nm. 
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3. AIM OF WORK 
3.1 AIM OF WORK 
 Hypertension is a chronic disorder very commonly seen among people. Current 
hypertension treatment guidelines recommend a goal of <140/90 mmHg for population 
with uncomplicated hypertension and goals are even lower (< 130/80 mmHg) for patients 
with diabetes or renal disease. These recommendations are supported by long-term trials 
suggesting that the greater the reduction in Blood Pressure, the greater the reduction in 
risk of cardiovascular events. Major clinical studies have shown that most patients 
require two or more drugs to achieve their Blood Pressure goals. Combination therapy 
should be used as initial treatment for patients in whom the probability of achieving BP 
control with monotherapy is low. Given the number of antihypertensive agents available, 
the number of potential combinations is large. However, rational choices should be based 
on some requirements. 
The prevalence of cardiovascular disease will undoubtedly increase as the mean 
age of the populations’ throughput the world increases. Heart disease is generally 
complex and multifactorial. Despite considerable advances in therapy, the underlying 
mechanisms are still rather poor. Efforts are directed towards the development of new 
drugs through the modification of the physicochemical properties of drug molecule, and 
the design and synthesis of new drugs with particular emphasis on drug delivery systems, 
pharmaceutical materials research, controlled drug release and targeting of drugs to the 
site of action to enhance the therapeutic effects. The perspective of the user enables the 
pharmacist and clinicians in understanding the factors leading to the suboptimal use of 
drugs in society. Identifying, solving and preventing drug-related problems in order to 
improve health and quality of life through pharmaceutical care in the community are 
therefore also important. Equally, the optimal utilization of pharmacist and clinician 
know – how will bring tremendous benefits to the patients from the viewpoint of social  
Pharmacy in the promotion of safe and efficient use of drugs. 
The use of combination drug therapy for cardiovascular (CV) disease risk 
reduction is the established approach to multiple risk factor reduction. The spectrum of 
rational combination products in CV disease prevention and treatment alone is extremely 
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broad. Development of fixed-dose combination drug products requires information 
beyond that needed for approval of single active ingredient products. Establishing the 
rationale and target populations for novel combinations, as well as the contributions of 
the component drugs to the claimed effects, and characterizing the pharmacokinetics, the 
pharmacodynamics, and clinical safety and efficacy of the combination are all necessary 
to support approval. 
Nowadays, Atorvastatin Calcium, Aspirin, Ramipril and Metoprolol Tartrate are 
the antihypertensive drugs in combined dosage form used for the treatment of prolonging 
hypertension and decrease LDL in CABG patients, and improve the quality of life. There 
are several methods were reported for the estimation of Atorvastatin Calcium, Aspirin 
Ramipril and Metoprolol Tartrate individually, two or three drugs combinations and the 
combination of these drugs with other drugs. But there are no methods were reported for 
estimation of these drugs in combined dosage form without prior separation. 
The non- availability of any UV-spectroscopy and HPTLC until now for the 
simultaneous analysis of the combination made it a worth-while objective to pursue the 
present work. 
Hence the present work was aimed to develop simple, precise and accurate 
methods for the estimation of Atorvastatin Calcium, Aspirin, Ramipril and Metoprolol 
Tartrate in bulk and in combined pharmaceutical dosage form and to validate the 
developed methods by UV-spectroscopy and HPTLC. 
3.2 PLAN OF WORK 
3.2.1 Survey on Literature 
 A complete literature survey was made on the drugs of Atorvastatin Calcium, 
Aspirin, Ramipril and Metoprolol Tartrate for the various physicochemical properties 
such as solubility, melting point and storage conditions etc. This survey gives some basic 
information of the drugs and the reported analytical methods of these drugs which help in 
the process of analytical method development. 
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3.2.2 Procurement of Raw Material and Formulation 
 The standard raw materials drugs of Atorvastatin Calcium, Aspirin, Ramipril, and 
Metoprolol Tartrate were obtained as the gift samples from Madras Pharmaceuticals, 
Chennai, India. ZYCAD-4, containing Atorvastatin Calcium- 10 mg, Aspirin- 75 mg, 
Ramipril- 5 mg and Metoprolol Tartrate- 50 mg was procured from Vasantha Medicals; 
Choolaimedu; Chennai. 
3.2.3 Method Development 
 The solubility of individual drugs was checked and from the list of solvents the 
common and stable solvent for the four drugs was selected. The solvent selected for both 
UV spectroscopy and HPTLC must be cheap and readily available. 
The various steps involved in the method development as follows, 
UV Spectroscopy 
   Selection of appropriate analytical wavelength and selection of suitable method 
   Determination of working concentration range 
   Analysis of synthetic mixture 
   Simultaneous analysis of the formulation by using the developed method 
HPTLC Method 
   Determination of suitable detection wavelength 
   Optimization of chromatographic conditions 
   Analysis of formulation 
   System suitability testing 
3.2.4 Validation 
 The method to be developed should be validated as per ICH and USFDA 
guidelines. The various parameters of validation are Linearity, Range, Precision, 
Accuracy, LOD, LOQ and Ruggedness.  
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4. MATERIALS AND METHODS 
4.1 MATERIALS 
4.1.1 Drug Sample 
 The raw materials were obtained from Madras Pharmaceuticals Chennai. 
4.1.2 Formulation Used 
 The formulations ZYCAD-4, containing Atorvastatin Calcium- 10 mg,      
Aspirin- 75 mg, Ramipril- 5 mg and Metoprolol Tartrate- 50 mg was purchased from 
Vasantha Medicals, Choolaimedu, Chennai. 
 4.1.3 Chemicals and Solvents Used  
 Methanol (AR grade), Methanol (HPLC grade), Benzene (AR grade),         
Toluene (AR grade), Ethyl Acetate (AR grade), Chloroform (AR grade) and           
Glacial Acetic Acid (AR grade) were purchased from Qualigens India Pvt. Limited, 
Mumbai and Loba Chemie India Limited, Mumbai. Distilled water was obtained from 
Double distillation unit in our laboratory. 
4.1.4 Instruments Used  
Different instruments used to carry out the work are, 
 Shimadzu AUX- 220 Digital balance. 
 Shimadzu- 1700 Double Beam UV-Visible Spectrophotometer with a pair of  
10 mm matched quartz cells. 
 ELICO SL-210 Double Beam UV- Visible Spectrophotometer with pair of   
10 mm matched quartz cells. 
 Soltec - Sonica Ultrsonic Cleaner - Model 2200 MH. 
 Remi Centrifuge Apparatus 
 Cyberlab Micropipette. 
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4.1.5 Specifications of Instruments 
4.1.5.1 Shimadzu AUX- 220 digital balance (Shimadzu instruction manual) 
SPECIFICATIONS 
Weighing capacity 200 gms 
Minimum display 0.1 mg 
Standard deviation ≤ 0.1 mg 
Operating temperature range 5 to 40° C 
4.1.5.2 Double beam UV-Visible Spectrophotometer (Shimadzu Instruction Manual) 
Model: Shimadzu, UV-1700; Cuvetts: 1 cm matched quartz cells. 
SPECIFICATIONS 
Light source 
20 W halogen lamp, Deuterium lamp. 
Light source position automatic adjustment 
mechanism 
Monochromators 
Aberration- correcting concave blazed 
holographic grating 
Detector Silicon photodiode 
Stray Light 
0.04% or less (220 nm: NaI 10 g/lt) 
0.04% or less (340 nm: NaNO2 50 g/lt) 
Measurement wavelength range 190 ~ 1100 nm 
Spectral band width 1nm or less (190 to 900 nm) 
Wavelength accuracy 
±0.5 nm on board automatic wavelength 
calibration mechanism 
Recording range 
Absorbance: -3.99~3.99 Abs 
Transmittance: -3.99~3.99 Abs 
Photometric accuracy 
±0.004 Abs (at 1.0 Abs), ±0.002 Abs (at 0.5 
Abs) 
Operating temperature/ 
humidity 
Temperature range: 15 to 35° C 
Humidity range: 35 to 80% (15 to below 30° C) 
35 to 70% (30 to below 35° C) 
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4.1.5.3 Elico - SL 210 Double Beams UV- Visible Spectrophotometer 
(Elico Instruction Manual) 
SPECIFICATIONS 
Light source 
Tungsten halogen lamp (W), Deuterium lamp 
(D2).  
Light source positions automatic adjustment 
mechanism 
Monochromators Concave holographic grating with 1200 lines/mm 
Detector Photodiode 
Stray light <0,05%T at 220 nm with NaI 10 g/lt 
Measurement Wavelength range 190 to 1100 nm 
Spectral Band Width 1.8 nm 
Wavelength Accuracy ±0.5 nm 
Spectral repeatability ±0.2 nm 
Spectral readability 0.1 nm 
Recording range ±3.0000 Abs 
Photometric accuracy ±0.005 Abs (at 1.0 Abs), ± 0.010 Abs (at 1.5 abs) 
Operating temperature/ Humidity 
Temperature range: 15 to 35º C 
Humidity range: 35 to 80% (15 to below 30º C) 
 35 to 70% (30 to below 35º C) 
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4.1.5.4 CAMAG Automatic TLC Sampler 4 (ATS4) 
APPLICATOR SPECIFICATIONS 
 
Spray gas Nitrogen 
Sample solvent type 
 
Methanol 
Spray gas temperature Unheated 
Syringe size 25 μl 
Number of tracks 15 
Application type Band 
Band length 8 mm 
 
4.1.5.5 CAMAG TLC Scanner 3 
SPECIFICATIONS 
Lamp D2 and W lamp 
Scanning Speed 20 mm/ sec 
Data Resolution 100 μm/ step 
Measurement Type Remission 
Measurement Mode Absorption 
Optical Filter Second Order 
Detector Mode Automatic 
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4.2 METHODS 
An effort was made to develop and validate simple, accurate and precise methods 
for the simultaneous analysis of Atorvastatin Calcium, Aspirin, Ramipril and Metoprolol 
Tartrate in bulk and in pharmaceutical dosage form by 
1. UV Spectroscopy 
First order derivative spectrophotometry 
2. HPTLC method. 
4.2.1 UV Spectroscopy 
4.2.1.1 First Order Derivative Spectrophotometry 
Derivative spectrophotometry involves the conversion of a normal spectrum to its 
first, second or higher derivative spectrum. The transformations that occur in the 
derivative spectra are understood by reference to a Gaussian band which represents an 
ideal absorption band. In the context of derivative spectrophotometry, the normal 
absorption spectrum is referred to as the fundamental, zero order or D° spectrum. The 
first derivative (D1) spectrum is a plot of the ratio of change of absorbance with 
wavelength against wavelength.  
4.2.1.1.2 Selection of Solvent 
 The solubility of drugs was determined in a variety of polar and non-polar 
solvents as per specification. The common and stable solvent was found to be Methanol 
and further dilutions were made with distilled water for the analysis of            
Atorvastatin Calcium, Aspirin, Ramipril and Metoprolol Tartrate for the proposed 
method. 
4.2.1.1.3 Preparation of Standard Stock Solutions 
 15 mg of Atorvastatin Calcium was weighed accurately and transferred in to 10 
ml volumetric flask. Dissolved with methanol and made up to the volume with methanol. 
The stock solution contains 1.5 mg/ ml of Atorvastatin Calcium 
 50 mg of Aspirin, Ramipril and Metoprolol Tartrate were accurately weighed and 
transferred in to 50 ml volumetric flask separately. Dissolved in methanol and made up to 
the volume to 50 ml. The solution contains 1 mg/ ml of Aspirin, Ramipril and Metoprolol 
Tartrate. 
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4.2.1.1.4 Selection of Wavelength  
 10 µg/ ml concentration solutions of Atorvastatin Calcium, Aspirin, Ramipril and 
Metoprolol Tartrate were prepared from the stock solution and the spectra were recorded 
between 200 and 400 nm by using distilled water as blank. The zero order spectra were 
derivitized to first order and the spectra were overlained. From the overlain spectra, the 
wavelength selected for the analysis were 291.5 nm, 247 nm 242.5 nm and 229.5 nm for 
Atorvastatin Calcium, Aspirin, Ramipril and Metoprolol Tartrate, respectively. 
4.2.1.1.5 Stability Studies 
 The stability of Atorvastatin Calcium, Aspirin, Ramipril and Metoprolol Tartrate 
were checked using 10 µg/ ml solutions at the selected wavelengths in different time 
intervals. It was found that Atorvastatin Calcium was stable for up to 3 hours, Aspirin up 
to 3 hours and 30 minutes, Ramipril up to 1 hour and 30 minutes, and Metoprolol Tartrate 
up to 1 hour. 
4.2.1.1.6 Linearity and Calibration 
 5 ml of Atorvastatin Calcium stock solution was pipetted out in to 50 ml 
volumetric flask and made up to 50 ml with distilled water. From that 1 – 7 ml were 
transferred in to a series of 50 ml volumetric flasks and made up to the volume with 
distilled water to get concentrations of 3 to 21 µg/ ml. 1 – 7 ml of the stock solutions of 
Aspirin, Ramipril and Metoprolol Tartrate were transferred in to series of 100 ml 
volumetric flask individually and made up to the volume with distilled water to get the 
concentrations of 10 – 70 µg/ ml of Aspirin, Ramipril and Metoprolol Tartrate. 
4.2.1.1.7 Synthetic Mixture 
 4 µg/ ml of Atorvastatin Calcium and 30 µg/ ml of Aspirin, Ramipril and 
Metoprolol Tartrate were prepared individually from their corresponding stock solutions. 
1 to 5 ml were pipetted out from each stock solution into a series of six100 ml volumetric 
flasks and made up to 100 ml with distilled water to get a mixture of Atorvastatin 
Calcium, Aspirin, Ramipril, and Metoprolol Tartrate in the concentration range of                     
4 to 20 µg/ ml for Atorvastatin Calcium and 30 to 70 µg/ ml for Aspirin, Ramipril, and 
Metoprolol Tartrate. The absorbances of the prepared synthetic mixtures were measured 
at the selected wavelengths. The amount of drugs in the prepared synthetic mixture was 
calculated. 
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 4.2.1.1.8 Quantification of Formulation  
 Twenty capsules (ZYCAD-4, containing Atorvastatin Calcium – 10 mg,     
Aspirin – 75 mg, Ramipril – 5 mg, Metoprolol Tartrate – 50 mg) were accurately 
weighed and the average weight was calculated. The capsules containing powder were 
crushed and made in to a fine powder. The mixed contents of capsule powder equivalent 
to 25 mg of Aspirin was accurately weighed and transferred in to a series of 25 ml 
volumetric flasks and added 15 mg/ ml solution of Ramipril. Dissolved in methanol and 
sonicated for15 minutes. The volume was made up to 25 ml with methanol and was 
centrifuged for 15 minutes at 2000 rpm. The solution was filtered through whatmann 
filter paper No.41. 3 ml of the stock solution was further diluted to 100 ml volumetric 
flask and made up to with distilled water to get the theoretical concentrations of 4 µg/ ml, 
30 µg/ ml, 20µg/ ml and 20 µg/ ml of Atorvastatin Calcium, Aspirin, Ramipril and 
Metoprolol Tartrate, respectively. The absorbances of solutions were measured at     
291.5 nm, 247 nm, 242.5 nm and 229.5 nm. The procedure was repeated for six times. 
The amounts of these drugs were calculated. 
4.2.1.1.9 Recovery Studies 
4.2.1.1.9.1 Preparation of Raw Material Standard Stock Solutions  
 10 mg of Atorvastatin Calcium raw material was weighed accurately in to a 10 ml 
volumetric flask, dissolved with methanol and made up to 10 ml with methanol to get a 
concentration of 1 mg/ ml of Atorvastatin Calcium. Similarly 100 mg of Aspirin, 
Ramipril and Metoprolol Tartrate raw material were weighed accurately and transferred 
in to 10 ml volumetric flasks separately, dissolved with methanol and made up to 10 ml 
with methanol to get concentrations of 10 mg/ ml of Aspirin, Ramipril and Metoprolol 
Tartrate. 
4.2.1.1.9.2 Recovery Procedure 
 The recovery study was done by adding a specified quantity of the drug to the 
pre-analyzed formulation. The tablet powder equivalent to 25 mg of Aspirin was weighed 
accurately and added 15 mg/ ml solution of Ramipril in to three separate 25 ml 
volumetric flasks. To this 2 ml, 3 ml, 4 ml of Atorvastatin Calcium, 2.0 ml, 2.5 ml, 3.0 ml 
of Aspirin, 1.0 ml, 1.5 ml, 2.0 ml of Ramipril and Metoprolol Tartrate stock solutions 
were added. Dissolved in methanol, sonicated for 15 minutes and made up to 25 ml with 
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methanol. The solution was centrifuged for 15 minutes at 2000 rpm and was filtered 
through whatmann filter paper No.41. From each solution, 3 ml was transferred to six 
100 ml volumetric flasks and made up to the volume with distilled water. The 
absorbances of the solutions were measured at 291.5 nm, 247 nm, 242.5 nm and 229.5 
nm. The amount of drug recovered was calculated. The procedure was repeated three 
times for each concentration. 
 
4.2.1.1.10 Validation of Developed Methods 
Linearity 
 A calibration curve was plotted with concentration versus the absorbance value. 
The linearity was checked for Atorvastatin Calcium in the concentration range of             
3 to 21 µg/ ml, Aspirin, Ramipril and Metoprolol Tartrate in the concentration range of 
10 to 70 µg/ ml. The drugs were found to be linear in the specified concentration ranges. 
Precision 
 The repeatability of the method was confirmed by repeated analysis of the 
formulation for six times with the same concentration. The amount of drug present in the 
formulation was calculated. The percentage RSD value was calculated. Confidence 
Interval (95%) was also calculated. 
 The intermediate precision was confirmed by the intraday and inter day analysis 
i.e. the analysis was performed three times on the same day and on three successive days. 
The amount of drug present in the formulation was calculated. The percentage RSD 
values were calculated. Confidence Interval (95%) was also calculated.  
Ruggedness 
 Ruggedness of the method was confirmed by the analysis of formulation in 
different analyst and by different instrument. The amount of drug was calculated and the 
percentage RSD values were also calculated. Confidence Interval (95%) was also 
calculated. 
Accuracy 
 Accuracy of the method was confirmed by recovery studies. To the pre-analyzed 
formulation a known quantity of the standard drug solutions were added and the amount 
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of drug recovered was calculated. The percentages RSD values were calculated. 
Confidence Interval (95%) was also calculated. 
LOD and LOQ 
 The linearity study was carried out for six times. The LOD and LOQ were 
calculated based up on the calibration curve method. The LOD and LOQ were calculated 
using the average of slope and standard deviation of intercept. 
4.2.2 HPTLC 
In HPTLC, the separation of the components of a mixture is based on the 
principle of adsorption. The HPTLC differ from the TLC in the size of silica gel used as 
the stationary phase and automated sampling application and detection. In the present 
study a twin through chamber and silica 60 F 254 were used. 
Selection of Stationary Phase 
  The resolution of Atorvastatin Calcium, Ramipril, Aspirin and Metoprolol 
Tartrate was achieved using TLC plate made up of silica gel G60 F 254 coated on an 
Aluminium support (E.Merck). The size of the silica gel particle was 2  and thickness of 
sorbent layer was 0.2 mm. The plates were supplied in 20 × 10 cm size which was cut in 
to appropriate sizes for method development. 
Selection of Mobile Phase 
 The mobile phase system was chosen based on the solubility and polarity of four 
drugs. The solution of drugs was prepared in methanol and used for spotting. Methanol 
gets vaporized soon after application on to the plate under nitrogen stream. After trying 
different mobile phase system an ideal system was chosen based on the resolution 
between compounds. The fixed mobile phase system for the separation of four drugs 
consisted of (mobile phase) with an appropriate Rf values. The drugs were scanned at 
224 nm after the development. 
The velocity of mobile phase in HPTLC is affected by the nature of the stationary 
phase (porosity, packing, particle size, etc), as well as mobile phase properties (viscosity, 
surface tension, vapour pressure of solvents, etc). Generally the velocity of mobile phase 
decreases during chromatographic development due to higher resistance of stationary 
phase densely packed with fine particles.  
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Different mixtures of mobile phase were tried to choose the ideal mobile phase 
with good resolution for the analysis. For that purpose select the mobile phase from 
previous journals and books the common mobile phase was Benzene, Ethyl Acetate, 
Toluene, Methanol, Chloroform and Glacial Acetic Acid They include the following 
Various mobile phase trials 
Mobile Phase Ratio 
Benzene: Ethyl Acetate: Toluene: 
Methanol: Glacial Acetic acid 
(4.5:4.0:1.0:0.5:0.1% v/v/v/v/v) 
Benzene: Ethyl Acetate: Toluene: 
Methanol: Glacial acetic acid 
(6.0:4.0:1.5:1.5:0.1% v/v/v/v/v) 
Benzene: Chloroform: Toluene: Methanol: 
Glacial Acetic acid 
(3.5:3.5:2.0:1.0:0.1% v/v/v/v/v) 
Benzene: Chloroform: Toluene: Methanol: 
Glacial Acetic Acid 
(3.5:3.5:1.5:1.5:0.1% v/v/v/v/v) 
 
Benzene: Chloroform: Toluene: Methanol: 
Glacial Acetic Acid 
(3.0:3.5:1.5:2.0:0.1% v/v/v/v/v) 
 
Benzene: Chloroform: Toluene: Methanol: 
Glacial Acetic Acid 
(3.0:3.0:1.5:2:5:0.1% v/v/v/v/v) 
 
Benzene: Chloroform: Toluene: Methanol: 
Glacial Acetic Acid 
(3.0:2.5:1.5:3.0:0.1% v/v/v/v/v) 
 
Benzene: Chloroform: Toluene: Methanol: 
Glacial Acetic Acid 
(2.5:3.0:1.5:3.0:0.1% v/v/v/v/v) 
 
Benzene: Chloroform: Toluene: Methanol: 
Glacial Acetic Acid 
(2.0:.3.0:1.5:3.5:0.1% v/v/v/v/v) 
 
Benzene: Carbon Tetra Chloride: Toluene: 
Methanol: Glacial Acetic Acid 
(4.0:4.5:0.5:1.0:0.1% v/v/v/v/v) 
 
Benzene: Toluene: Methanol: Glacial 
Acetic Acid 
(6.5:2.0:1.5:0.1% v/v/v/v) 
 
Benzene: Toluene: Methanol: Glacial 
Acetic Acid 
(7.5:1.0:1.5:0.1% v/v/v/v)  
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From the above list of mobile phase the mobile phase Benzene: Toluene: 
Methanol: Glacial Acetic Acid (7.5:1.0:1.5:0.1% v/v/v/v) was found to be an ideal mobile 
phase with good resolution between the spots.  
Optimization of Variants in TLC 
 The composition of mobile phase, chamber saturation (equilibration time), plate 
equilibration time, the distance of solvent development and bandwidth of the spot are a 
few variants affect Rf values of drugs. 
Chamber Saturation (Equilibration time) 
Chamber saturation is done so that equilibration is established eventually between the 
components of developing solvents and their vapour phase and the formation of 
secondary solvent fronts could be avoided 
Hence in the current study chamber saturation was taken in to consideration to 
achieve reproducible Rf values and peak area. The mobile phase was placed on one side 
of twin through chamber and shaken well. Different saturation times were maintained for 
different mobile phase. The chamber saturation time for Benzene: Toluene: Methanol: 
Glacial Acetic Acid (7.5:1.0:1.5:0.1% v/v/v/v) was 30 minutes. 
Selection of Detection Wavelength 
 By comparing the spectral characters of Atorvastatin Calcium, Ramipril, Aspirin 
and Metoprolol Tartrate the detection wavelength was selected for the method 224 nm 
was selected for as the detection wavelength with reference to the spectral conformation 
graph.  
4.2.2.1Optimized Chromatographic Conditions 
 After conforming with the mobile phase and detection wavelength, the optimized 
conditions for the method was as follows  
Stationary Phase  - Silica Gel 60 F 254 HPTLC Plates  
Mobile Phase   - Benzene: Toluene: Methanol: Glacial Acetic Acid 
Mobile Phase ratio  - 7.5: 1.0: 1.5: 0.1 % v/v/v/v 
Detection   - CAMAG TLC scanner 3, at 224 nm 
Temperature   - Room Temperature 
Chamber   -  Twin through Chamber   
Development Mode  - Ascending Mode  
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4.2.2.2 Preparation of Standard Stock Solution 
 100 mg of Metoprolol Tartrate, 10 mg of Ramipril, 20 mg of Atorvastatin 
Calcium, and 75 mg of Aspirin raw materials were accurately weighed in to 100 ml 
volumetric flask, dissolved in methanol and made up to the volume with methanol. This 
solution contains 1 mg/ ml of Metoprolol Tartrate, 100 µg/ ml of Ramipril, 200 µg/ ml of 
Atorvastatin Calcium and 750 µg/ ml of Aspirin. 
4.2.2.3 Linearity and Calibration Curve  
   1 ml of the stock solutions was pipetted out in to 10 ml volumetric flasks and 
made up to the volume with methanol. 1 ng/ µl – 6 ng/ µl were spotted on TLC plates and 
to get the concentration range of 100 – 600 ng/ µl, 10 – 60 ng/ µl, 20 – 120 ng/ µl and   
75 – 450 ng/ µl of Metoprolol Tartrate, Ramipril, Atorvastatin Calcium and Aspirin, 
respectively. 
4.2.2.4 Quantification of Formulation 
 Twenty capsules were weighed accurately and the average weight of each capsule 
was determined. Powdered the mixed contents of capsule powder and weighed accurately 
a quantity of the capsule powder equivalent to 75 mg of Aspirin in to a series of six     
100 ml volumetric flasks. Dissolved in methanol and sonicated for 15 minutes. The 
volume was made up to 50 ml with methanol and was centrifuged for 15 minutes at 2000 
rpm. The solution was filtered through whatmann filter paper No.41. 1 ml of the filtrate 
was further diluted to 10 ml with methanol. The solution contains 100 ng/ µl,     10 ng/ 
µl, 20 ng/ µl and 150 ng/ µl of Metoprolol Tartrate, Ramipril, Atorvastatin Calcium and 
Aspirin theoretically. 1 µl spots were placed on the plates and the chromatogram was 
developed in the twin through chamber. From the peak area and amount of drugs were 
calculated. The procedure was repeated for six times. 
4.2.2.5 Recovery Studies 
4.2.2.5.1 Preparation of Raw Material Standard Stock Solutions 
 200 mg of Metoprolol Tartrate, 20 mg of Ramipril, 40 mg of Atorvastatin 
Calcium and 300 mg of Aspirin raw materials were weighed accurately in to 10 ml 
volumetric flasks individually, dissolved with methanol and made up to the volume with 
methanol to get a concentration of 20 mg/ ml, 2 mg/ ml, 4 mg/ ml and 30 mg/ ml of 
Metoprolol Tartrate, Ramipril, Atorvastatin Calcium and Aspirin. 
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4.2.2.5.2 Recovery Procedure 
 The recovery study was done by adding a specified quantity of the drug to the 
pre-analyzed formulation. The tablet powder equivalent to 75 mg of Aspirin was weighed 
accurately in to three separate 50 ml volumetric flasks. To this 2 ml, 2.5 ml and 3 ml of 
Metoprolol Tartrate, Ramipril, Atorvastatin Calcium and Aspirin stock solutions were 
added. Dissolved in methanol, sonicated for 15 minutes and made up to 50 ml with 
methanol. The solutions were centrifuged for 15 minutes at 2000 rpm and were filtered 
through Whatmann filter paper No.41. From each solution, 1 ml was transferred to six   
10 ml volumetric flasks and made up to the volume with methanol. From this solution,    
1 l quantity of sample was spotted and the chromatogram was recorded. From the peak 
area, the amount of drug recovered was calculated. The procedure was repeated three 
times for each concentration. 
 
4.2.2.6 Validation of Developed Method 
Linearity 
A calibration curve was plotted with concentration versus the peak area. The 
linearity range was checked for in the concentration range of 100 – 600 ng/ µl,               
10 – 60 ng/ µl, 20 – 120 ng/ µl and 75 – 450 ng/ µl of Metoprolol Tartrate, Ramipril, 
Atorvastatin Calcium and Aspirin, respectively. The drugs were found to be linear in the 
specified concentration ranges. 
Precision 
 The repeatability of the method was checked by repeated analysis of the 
formulation for six times with the same concentration. The amount of drug present in the 
formulation was calculated. The percentage RSD value was calculated. Confidence 
Interval (95%) was also calculated. 
 The intermediate precisions were confirmed by the intraday and inter day analysis 
i.e. the analysis was performed three times on the same day and on three successive days. 
The amount of drug present in the formulation was calculated. The percentage RSD 
values were calculated. Confidence Interval (95%) was also calculated. 
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Accuracy   
Accuracy of the method was confirmed by recovery studies. To the pre-analyzed 
formulation a known quantity of the standard drug solutions were added and the amount 
of drug recovered was calculated. The percentages RSD values were calculated. 
Confidence Interval (95%) was also calculated. 
LOD and LOQ 
 The linearity study was carried out for three times. The LOD and LOQ were 
calculated based up on the calibration curve method. The LOD and LOQ were calculated 
using the average of slope and standard deviation of intercept. 
 
 
 
RESULTS AND 
DISCUSSION 
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5. RESULTS AND DISSCUSION 
Simultaneous estimation of four drugs in a formulation has more advantages such 
as accurate, less use of reagent and less time requirement for the estimation rather than 
individual estimation of four drugs. The simple, precise and accurate analytical 
techniques were developed for the simultaneous estimation of Atorvastatin Calcium, 
Ramipril, Metoprolol Tartrate and Aspirin in bulk and in pharmaceutical dosage form. 
The methods include 
1. UV Spectroscopy 
 First Order Derivative Spectrophotometry 
2. HPTLC Method 
5.1 UV Spectroscopy 
5.1.1 First Order Derivative Spectrophotometry 
 A simple, precise and accurate first order derivative spectrophotometric method 
was developed and validated for the simultaneous estimation of Atorvastatin Calcium, 
Aspirin, Ramipril and Metoprolol Tartrate in bulk and in combined dosage form. The 
drugs were identified by the melting point and IR spectrum, the IR spectrum of 
Atorvastatin Calcium, Ramipril, Metoprolol Tartrate and Aspirin were given in figures 1, 
2, 3 and 4, respectively. The solubility of drugs in various polar and non polar solvents 
checked as per I.P guidelines. All the drugs were exhibited different solubility characters. 
From the solubility data, the common solvents were found to be methanol, acetonitrile, 
acetone, dichloromethane and alkaline borate buffer (pH 9). The solvents such as 
acetonitrile, acetone, dichloromethane and alkaline borate buffer (pH 9) were not selected 
because the cut off wavelength of these solutions were above 240 nm and the solvent 
interference should be expected during the analysis. Hence, methanol was selected as the 
common solvent and it was used for the preparation of stock solution. Further dilutions 
were made with distilled water. The solubility profile of Atorvastatin Calcium, Aspirin, 
Ramipril and Metoprolol Tartrate were given in tables 1, 2, 3, and 4, respectively. 
 10 µg/ ml concentration solutions of Atorvastatin Calcium, Aspirin, Ramipril and 
Metoprolol Tartrate were prepared and the spectra were recorded. The overlain zero order 
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spectra are shown in figure 5. By observing the spectral characters of Atorvastatin 
Calcium, Aspirin, Ramipril and Metoprolol Tartrate, the methods used for the multi 
component analysis viz. simultaneous equation method, absorption correction method 
and absorption ratio method were not applied, because the interference were more. Hence 
the normal curve was derivitized to first order, and overlained and shown in figure 6. 
From the overlain spectra 291.5 nm, 247 nm, 242.5 nm and 229.5 nm were selected for 
the simultaneous estimation of Atorvastatin Calcium, Aspirin, Ramipril and Metoprolol 
Tartrate, respectively. At 291.5 nm, Atorvastatin Calcium has the absorbance where as 
Aspirin, Ramipril and Metoprolol Tartrate has no absorbance. Hence this wavelength 
selected for the analysis of Atorvastatin Calcium without the interference of other three 
drugs. At 247 nm Atorvastatin Calcium and Aspirin were showed marked absorbance 
whereas Ramipril and Metoprolol Tartrate have zero crossing points. The absorbance of 
Atorvastatin Calcium was interfered in the analysis of Aspirin. Hence, the absorbance of 
Atorvastatin Calcium was corrected for interference from the total absorbance value. 
With the help of corrected absorbance the amount of Aspirin was calculated at 247 nm. 
At 242.5 nm Atorvastatin Calcium, Aspirin and Ramipril were showed marked 
absorbance and Metoprolol Tartrate have zero crossing point. The absorbance of 
Atorvastatin Calcium and Aspirin were interfered in the analysis of Ramipril. Hence, the 
absorbance of Atorvastatin Calcium and Aspirin were corrected for interference from the 
total absorbance value. With the help of the corrected absorbance, the amount of 
Ramipril was calculated at 242.5 nm. At 229.5 nm Atorvastatin Calcium, Aspirin, 
Ramipril and Metoprolol Tartrate were showed the absorbance of Atorvastatin Calcium, 
Aspirin and Ramipril were interfered in the analysis of Metoprolol Tartrate. Hence, the 
absorbance of Atorvastatin Calcium, Aspirin and Ramipril were corrected for 
interference from the total absorbance value. The corrected absorbance value was used 
for the analysis of Metoprolol Tartrate at 229.5 nm.       
The stability of Atorvastatin Calcium, Aspirin, Ramipril and Metoprolol Tartrate 
were checked at the selected wavelengths using methanol and distilled water as solvent. It 
was found that Atorvastatin Calcium stable for about 3 hours, Aspirin for about 3 hours 
and 30 minutes, Ramipril for about 1 hour and 30 minutes and Metoprolol Tartrate for 
about 1 hour. 
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Various aliquots of Atorvastatin Calcium, Aspirin, Ramipril and Metoprolol 
Tartrate were prepared in the concentration range of 3 - 21 µg/ ml, 10 – 70 µg/ ml,        
10 - 70 µg/ ml and 10 - 70 µg/ ml, respectively. The absorbances of these solutions were 
measured at the selected wavelengths. The calibration curve was constructed using 
concentration versus absorbance. The preparation of calibration curve was repeated for 
six times for each drug at their selected wavelengths. The optical parameters like Molar 
absorptivity, Sandell’s sensitivity, Correlation coefficient, Slope, Intercept, LOD and 
LOQ were calculated. The correlation coefficient for all the four drugs was found to be 
above 0.999. This indicates that all the drugs obey Beer’s law in the selected 
concentration ranges. Hence the concentrations were found to be linear. The calibration 
graph for Atorvastatin Calcium at 291.5 nm is shown in figure 7. The calibration curves 
for Atorvastatin Calcium and Aspirin at 247 nm are shown in figure 8 and 9, respectively. 
The calibration curves for Atorvastatin Calcium, Aspirin and Ramipril at 242.5 nm are 
shown in figure 10, 11 and 12, respectively. At 229.5 nm, the calibration curves for 
Atorvastatin Calcium, Aspirin, Ramipril and Metoprolol Tartrate are shown in figure 13, 
14, 15 and 16, respectively. The optical characteristics of the drugs at their selected 
wavelengths are shown in tables 5, 6, 7, and 8, respectively. 
The developed method was applied for the analysis of synthetic mixture to find 
out the developed method was correct or not. The amount of Atorvastatin Calcium, 
Aspirin, Ramipril and Metoprolol Tartrate were found to be in the range of                 
98.00 - 100.87%, 98.16 - 100.36%, 99.22 - 100.84% and 100.23 – 101.21%, respectively. 
The results are listed in table 9. The amount found was good agreement with the expected 
concentration. Hence it was planned to apply for the analysis of formulation. 
The capsule formulation ZYCAD-4 (containing Atorvastatin Calcium- 10 mg, 
Aspirin – 75 mg, Ramipril- 5 mg and Metoprolol Tartrate- 50 mg) was selected for the 
analysis. The drugs Atorvastatin Calcium, Aspirin, Ramipril and Metoprolol Tartrate in 
the ratio of 2: 15: 1: 10 in the formulation. The percentage purity of the drugs in the 
formulation was found to be 102.76 ± 1.4487, 99.00 ± 1.5795, 99.95 ± 1.7250 and     
98.66 ± 0.8496 for Atorvastatin Calcium, Aspirin, Ramipril, and Metoprolol Tartrate, 
respectively. The results are listed in table 10.The confidence interval (95%) for drugs 
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was found to be in the range of 101.23 – 104.28, 97.34 – 100.65,   98.13 – 101.76 and     
97.76 – 99.55 for Atorvastatin Calcium, Aspirin, Ramipril, and Metoprolol Tartrate, 
respectively. The precision of the method was confirmed by the repeated analysis of 
formulation for six times. The percentage RSD values were found to be 1.4097, 1.5954, 
1.7257 and 0.8612 for Atorvastatin Calcium, Aspirin, Ramipril and Metoprolol Tartrate, 
respectively. 
Further the precision of the method was confirmed by intraday and inter day 
analysis. Intraday and inter day analysis of formulation was done on three times on same 
day and one time on three consecutive days. The percentage RSD for the intraday and 
inter day precision was found to be 0.1528 and 0.0680 for Atorvastatin Calcium,     
0.8116 and 0.3145 for Aspirin, 1.9063 and 1.1612 for Ramipril and 1.7204 and 1.0513 
for Metoprolol Tartrate, respectively. The results are listed in table 11. The low 
percentage RSD values indicated that the precision of the method was confirmed. The 
confidence interval (95%) of intraday analysis were found to be in the range of       
101.48 – 102.25, 97.15 – 101.14, 96.06 – 105.61 and 95.25 – 103.76 for Atorvastatin 
Calcium, Aspirin, Ramipril and Metoprolol Tartrate, respectively. The confidence 
interval (95%) of inter day analysis were found to be in the range of 101.72 – 102.07, 
98.57 – 100.12, 98.25 – 104.08 and 96.24 – 101.41 for Atorvastatin Calcium, Aspirin, 
Ramipril and Metoprolol Tartrate, respectively.  
The ruggedness of the method was validated by using different analysts and 
different instruments. The percentage RSD for analyst 1 and analyst 2 were found to be 
1.3842 and 0.2887 for Atorvastatin Calcium, 1.5954 and 1.8396 for Aspirin, 1.7256 and 
1.8602 for Ramipril and 0.8611 and 0.8367 for Metoprolol Tartrate, respectively. The 
percentage RSD for instrument 1 and instrument 2 were found to be 1.1602 and 1.5153 
for Atorvastatin Calcium, 0.6684 and 0.4462 for Aspirin, 1.9820 and 1.0782 for Ramipril 
and 1.2887 and 0.8223 for Metoprolol Tartrate, respectively. The results are listed in 
table 12. The Confidence interval (95%) of different analyst 1 was found to be in the 
range of 101.23 -104.22, 97.34 – 100.65, 98.13 – 101.76 and 97.76 – 99.55 for             
Atorvastatin Calcium, Aspirin, Ramipril and Metoprolol Tartrate, respectively. The 
Confidence interval (95%) of different analyst 2 was found to be in the range of      
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101.63 -102.24, 97.60 – 101.45, 98.03 – 101.94 and 98.20 – 99.93 for Atorvastatin 
Calcium, Aspirin, Ramipril and Metoprolol Tartrate, respectively. The Confidence 
interval (95%) of different instrument 1 was found to be in the range of 101.87 -102.22, 
98.70 – 100.09, 99.00 – 103.21 and 97.63 – 100.30 for Atorvastatin Calcium, Aspirin, 
Ramipril and Metoprolol Tartrate, respectively. The Confidence interval (95%) of 
different instrument 2 was found to be in the range of 98.37 - 101.54, 98.54 – 99.47, 
98.67 – 100.92 and 98.17 – 99.88 for Atorvastatin Calcium, Aspirin, Ramipril and 
Metoprolol Tartrate, respectively. 
The accuracy of the method was confirmed by the recovery studies. To the pre-
analyzed formulation, a known quantity of raw material was added and the percentage 
recovery was calculated. The percentage of raw material added was 60%, 90%, and 120% 
for Atorvastatin Calcium, Ramipril and Metoprolol Tartrate and 80%, 100% and 120% 
for Aspirin. The percentage recovery was found to be in the range of 99.76 - 100.45% for 
Atorvastatin Calcium, 100.38 - 101.08% for Aspirin, 98.58 - 101.64% for Ramipril and 
98.33 - 101.69% for Metoprolol Tartrate. The percentage RSD value was found to be 
0.3508 for Atorvastatin Calcium, 0.3506 for Aspirin, 1.5580 for Ramipril and 1.8860 for 
Metoprolol Tartrate. The low percentage RSD indicated there was no interference due to 
excipients used in formulation. Hence, the accuracy method was conformed. The results 
are listed in table 13. The confidence interval (95%) for drugs was found to be in the 
range of 99.52 – 101.27, 99.82 – 101.57,   96.40 – 104.17 and 94.85 – 104.18 for 
Atorvastatin Calcium, Aspirin, Ramipril, and Metoprolol Tartrate, respectively.   
5.2 HPTLC Method  
 An effort was made to develop a simple, precise and accurate method for the 
simultaneous estimation of Metoprolol Tartrate, Ramipril, Atorvastatin Calcium and 
Aspirin in bulk and in pharmaceutical dosage form by HPTLC method. 
 The initial separation was based up on the solubility of drugs, the different mobile 
phase were tried to get the better resolution. The different mixtures of the mobile phase 
tried were Benzene : Ethyl Acetate : Toluene : Methanol : Glacial Acetic Acid, Benzene : 
Chloroform : Toluene : Methanol : Glacial Acetic Acid and Benzene : Toluene : 
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Methanol : Glacial Acetic Acid with different ratios. In Benzene : Toluene : Methanol : 
Glacial Acetic Acid, all the drugs were well separated with good resolution when 
compared to other mobile phases. By altering the composition of Benzene the separation 
was affected more. Hence the chromatograms were recorded by changing the 
concentration of Benzene. In the mobile phase, Benzene : Toluene : Methanol : Glacial 
Acetic Acid in the ratio of 7.5: 1.0: 1.5: 0.1, all the drugs were eluted with better 
resolution. Hence this was selected as the mobile phase for the analysis of        
Metoprolol Tartrate, Ramipril, Atorvastatin Calcium and Aspirin. With the above 
selected mobile phase the UV spectra of all the drugs were recorded and overlained. 
From the overlain spectra, at 224 nm all the drugs showed marked absorbance. Hence this 
was selected as the detection wavelength and shown is figure 17. 
 With the optimized chromatographic conditions, the chromatograms were 
recorded and shown in figures 18, 19, 20 and 21 for Metoprolol Tartrate, Ramipril, 
Atorvastatin Calcium and Aspirin, respectively. The Rf value for Metoprolol Tartrate, 
Ramipril, Atorvastatin Calcium and Aspirin were found to be 0.14 ± 0.01, 0.26 ± 0.01, 
0.40 ± 0.01 and 0.99 ± 0.01, respectively. 
 The linearity range was fixed as 100 – 600 ng/ µl for Metoprolol Tartrate,          
10 – 60 ng/ µl for Ramipril, 20 – 120 ng/ µl for Atorvastatin Calcium and                        
75 – 450 ng/ µl for Aspirin in methanol and shown in figures 22 – 27. The calibration 
graph was recorded using peak area and concentration and these are shown in figures         
28 – 31. The correlation coefficients were found to be 0.9999, 0.9998, 0.9998 and 0.9998 
for Metoprolol Tartrate, Ramipril, Atorvastatin Calcium and Aspirin, respectively. The 
optical characteristics such as the Correlation coefficient, Slope, Intercept, LOD and 
LOQ and were calculated and shown in tables 14 – 17. The correlation coefficient values 
indicated that the selected concentration was linear.  
 The capsule dosage form ZYCAD-4 was selected for the analysis. The 
chromatogram for the analysis of formulation was shown in figures 32 – 37. The 
percentage purity of Metoprolol Tartrate, Ramipril, Atorvastatin Calcium and Aspirin 
were found to be 100.24 ± 0.8348, 99.93 ± 0.5910, 99.00 ± 0 .6526 and 99.97 ± 0.0829, 
88 
 
respectively. The results of analysis are shown in table 18. The confidence interval (95%) 
for drugs was found to be in the range of 99.36 – 101.11, 99.30 – 100.55, 98.31 – 99.68 
and 99.88 – 100.05 for Metoprolol Tartrate, Ramipril, Atorvastatin Calcium and Aspirin, 
respectively. Precision of the method was confirmed by repeated analysis of formulation 
for six times. The percentage RSD values were found to be 0.8328, 0.5914, 0.6593 and 
0.0830 for Metoprolol Tartrate, Ramipril, Atorvastatin Calcium and Aspirin, respectively. 
 Further the precision of the method was confirmed by intraday and inter day 
analysis. Intraday and inter day analysis of formulation was done on three times on same 
day and one time on three consecutive days. The percentage RSD values for the intraday 
and inter day precision was found to be 0.7639 and 1.2832 for Metoprolol Tartrate,                
0.7197 and 1.1052 for Ramipril, 0.1547 and 2.0167 for Atorvastatin Calcium and   
0.3158 and 0.1399 for Aspirin. The results of analysis are shown in table 19. The 
confidence interval (95%) of intraday analysis were found to be in the range of 98.14 – 
101.93, 98.40 – 101.99,    98.35 – 99.10 and 98.97 - 100.54 for Metoprolol Tartrate, 
Ramipril, Atorvastatin Calcium and Aspirin, respectively. The confidence interval (95%) 
of inter day analysis were found to be in the range of 96.88 – 101.27, 96.92 – 102.39, 
95.20 – 105.19 and 99.69 – 100.38 for Metoprolol Tartrate, Ramipril, Atorvastatin 
Calcium and Aspirin, respectively.  
 The accuracy of the method was confirmed by the recovery studies. To the      
pre-analyzed formulation, a known quantity of raw material was added and the 
percentage recovery was calculated. The percentage of raw material added was 80%, 
100% and 120% for all four drugs. The chromatograms for the recovery analysis are 
shown in figures 38 – 40. The percentage recovery was found to be in the range of         
99.00 - 99.99%, for Metoprolol Tartrate 99.86 - 101.26% for Ramipril, 98.03 - 101.98 for 
Atorvastatin Calcium and 98.40 - 98.71 for Aspirin. The percentage RSD values were 
found to be 0.5087, 0.6978, 1.6383 and 0.1787 for Metoprolol Tartrate, Ramipril, 
Atorvastatin Calcium and Aspirin, respectively. The low percentage RSD value indicates 
that there was no interference due to the excipients used in formulation during the 
analysis. The data of recovery analysis are listed in table 20. The confidence interval 
(95%) for drugs was found to be in the range of 98.29 – 100.80, 98.84 – 102.33,       
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96.49 – 104.70 and 98.16 – 99.03 for Metoprolol Tartrate, Ramipril, Atorvastatin 
Calcium and Aspirin, respectively. 
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6. SUMMARY AND CONCLUSION 
 Two simple, precise and accurate methods were developed for the simultaneous 
estimation of Atorvastatin Calcium, Aspirin, Ramipril and Metoprolol Tartrate in bulk 
and in pharmaceutical dosage form. 
 The methods developed were 
1. UV Spectroscopy 
  First Order Derivative Spectrophotometry 
2. HPTLC Method 
6.1 UV Spectroscopy  
6.1.1 First Order Derivative Spectrophotometry 
 From the solubility profile, methanol was chosen as the common solvent for the 
simultaneous analysis of Atorvastatin Calcium, Aspirin, Ramipril and Metoprolol 
Tartrate. The spectra of all the drugs recorded and are derivitized to first order. From the 
overlain first order derivative spectra 291.5 nm, 247 nm, 242.5 nm and 229.5 nm were 
selected for the analysis of Atorvastatin Calcium, Aspirin, Ramipril and Metoprolol 
Tartrate, respectively. 
 Beer’s law obeyed the concentration range of 3 to 21 µg/ ml, 10 to 70 µg / ml,      
10 to 70 µg/ ml and 10 to 70 µg / ml for Atorvastatin Calcium, Aspirin, Ramipril, and 
Metoprolol Tartrate, respectively. The calibration graphs were plotted. The correlation 
coefficient values for all the drugs were more than 0.999.  The optical parameters like the 
Molar absorptivity, Sandell’s sensitivity, Correlation coefficient, Slope, Intercept, LOD 
and LOQ, and were calculated. 
The developed method was applied for the analysis of synthetic mixture to find 
out the developed method was correct or not. The amount of Atorvastatin Calcium, 
Aspirin, Ramipril and Metoprolol Tartrate were found to be in the range of                 
98.00 - 100.87%, 98.16 - 100.36%, 99.22 - 100.84% and 100.23 – 101.21%, respectively. 
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The amount found was good agreement with the expected concentration. Hence it was 
planned to apply for the analysis of formulation. 
ZYCAD-4 capsule containing Atorvastatin Calcium 10 mg, Aspirin 75 mg,  
Ramipril 5 mg and Metoprolol Tartrate 50 mg and was selected for the analysis. The 
percentage of drugs in the formulation was found to be 102.76 ± 1.4487, 99.00 ± 1.5795, 
99.95 ± 1.7250 and 98.66 ± 0.8496 for Atorvastatin Calcium, Aspirin, Ramipril, and 
Metoprolol Tartrate, respectively. The confidence interval (95%) for drugs was found to 
be in the range of 101.23 – 104.28, 97.34 – 100.65,   98.13 – 101.76 and 97.76 – 99.55 
for Atorvastatin Calcium, Aspirin, Ramipril, and Metoprolol Tartrate, respectively.   
 The precision of the method was confirmed by the repeatability studies. The 
percentages RSD were found to be 1.4097, 1.5954, 1.7257 and 0.8612 for       
Atorvastatin Calcium, Aspirin, Ramipril, and Metoprolol Tartrate, respectively. 
Further the precision of the method was confirmed by intraday and      inter day 
analysis. The percentages RSD values for intraday and inter day were found to be 0.1528 
and 0.0680 for Atorvastatin Calcium, 0.8116 and 0.3145 for Aspirin, 1.9063 and 1.1612 
for Ramipril and 1.7204 and 1.0513 for Metoprolol Tartrate, respectively. The confidence 
interval (95%) of intraday analysis were found to be in the range of 101.48 – 102.25, 
97.15 – 101.14, 96.06 – 105.61 and 95.25 – 103.76 for Atorvastatin Calcium, Aspirin, 
Ramipril and Metoprolol Tartrate, respectively. The confidence interval (95%) of inter 
day analysis were found to be in the range of 101.72 – 102.07, 98.57 – 100.12,          
98.25 – 104.08 and 96.24 – 101.41 for Atorvastatin Calcium, Aspirin, Ramipril and 
Metoprolol Tartrate, respectively.  
 The ruggedness of the method was confirmed by performing the analysis with the 
different analysts and different instruments. The percentage RSD values for different 
analysts were found to be 1.3842 and 0.2887 for Atorvastatin Calcium,                    
1.5954 and 1.8396 for Aspirin, 1.7256 and 1.8602 for Ramipril and 0.8611 and 0.8367 
for Metoprolol Tartrate, for analyst 1 and analyst 2, respectively. The percentage RSD 
values for different instruments were found to be 1.1602 and 1.5153 for Atorvastatin 
Calcium, 0.6684 and 0.4463 for Aspirin, 1.9820 and 1.0782 for Ramipril and 1.2887 and 
92 
 
0.8223 for Metoprolol Tartrate, for instrument 1 and instrument 2, respectively. The 
Confidence interval (95%) of different analyst 1 was found to be in the range of 101.23 -
104.22, 97.34 – 100.65, 98.13 – 101.76 and 97.76 – 99.55 for Atorvastatin Calcium, 
Aspirin, Ramipril and Metoprolol Tartrate, respectively. The Confidence interval (95%) 
of different analyst 2 was found to be in the range of 101.63 -102.24, 97.60 – 101.45, 
98.03 – 101.94 and 98.20 – 99.93 for Atorvastatin Calcium, Aspirin, Ramipril and 
Metoprolol Tartrate, respectively. The Confidence interval (95%) of different instrument 
1 was found to be in the range of 101.87 -102.22, 98.70 – 100.09, 99.00 – 103.21 and 
97.63 – 100.30 for Atorvastatin Calcium, Aspirin, Ramipril and Metoprolol Tartrate, 
respectively. The Confidence interval (95%) of different instrument 2 was found to be in 
the range of 98.37 - 101.54, 98.54 – 99.47, 98.67 – 100.92 and 98.17 – 99.88 for 
Atorvastatin Calcium, Aspirin, Ramipril and Metoprolol Tartrate, respectively. 
 The accuracy of the method was confirmed by recovery studies. To the 
preanalysed formulation the different amount of raw material were added and the amount 
of drugs recovered were calculated. The percentage recovery was found to be in the range 
of 99.76 - 100.45% for Atorvastatin Calcium, 100.38 - 101.08% for Aspirin,                  
98.58 -101.64% for Ramipril and 98.33 - 101.69% for Metoprolol Tartrate. The 
percentage RSD value was found to be 0.3508 for Atorvastatin Calcium, 0.3506 for 
Aspirin, 1.5580 for Ramipril and 1.8860 for Metoprolol Tartrate. The confidence interval 
(95%) for drugs was found to be in the range of 99.52 – 101.27, 99.82 – 101.57,                  
96.40 – 104.17 and 94.85 – 104.18 for Atorvastatin Calcium, Aspirin, Ramipril, and 
Metoprolol Tartrate, respectively.   
6.2 HPTLC Method 
  The simple, precise and accurate HPTLC method was developed for the 
simultaneous estimation of Metoprolol Tartrate, Ramipril, Atorvastatin Calcium and 
Aspirin in bulk and in pharmaceutical dosage form. 
 The mobile phase consists of Benzene: Toluene: Methanol: Glacial Acetic Acid 
(7.5: 1.0: 1.5: 0.1% v/v/v/v) was selected for the analysis. From the spectral 
characteristics, 224 nm was selected as detection wavelength for the analysis. 
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 Beer’s law obeyed the concentration range of 100 – 600 ng/ µl, 10 – 60 ng/ µl,    
20 – 120 ng/ µl and 75 – 450 ng/ µl for Metoprolol Tartrate, Ramipril,            
Atorvastatin Calcium and Aspirin, respectively. The calibration graphs were plotted. The 
correlation coefficient values for all the drugs were more than 0.999. The optical 
parameters like the Correlation coefficient, Slope, Intercept, LOD and LOQ were 
calculated. 
  ZYCAD-4 capsule containing Atorvastatin Calcium 10 mg, Aspirin 75 mg 
Ramipril 5 mg and Metoprolol Tartrate 50 mg was selected for the analysis. The 
percentage of drugs in the formulation was found to be 100.24 ± 0.8348, 99.93 ± 0.5910, 
99.00 ± 0.6526 and 99.97 ± 0.0829 for Metoprolol Tartrate, Ramipril, Atorvastatin 
Calcium and Aspirin, respectively. The confidence interval (95%) for drugs was found to 
be in the range of 99.36 – 101.11, 99.30 – 100.55, 98.31 – 99.68 and 99.88 – 100.05 for 
Metoprolol Tartrate, Ramipril, Atorvastatin Calcium and Aspirin, respectively. 
Precision of the method was confirmed by repeated analysis of formulation for six 
times. The percentage RSD values were found to be 0.8328, 0.5914, 0.6593 and 0.0830 
for Metoprolol Tartrate, Ramipril, Atorvastatin Calcium and Aspirin, respectively. 
Further the precision of the method was confirmed by intraday and inter day 
analysis. The percentage RSD values for the intraday and inter day precision was found 
to be 0.7639 and 1.2832 for Metoprolol Tartrate, 0.7197 and 1.1052 for Ramipril,   
0.1547 and 2.0167 for Atorvastatin Calcium and 0.3158 and 0.1399 for Aspirin. The 
confidence interval (95%) of intraday analysis were found to be in the range of         
98.14 – 101.93, 98.40 – 101.99,    98.35 – 99.10 and 98.97 100.54 for Metoprolol 
Tartrate, Ramipril, Atorvastatin Calcium and Aspirin, respectively. The confidence 
interval (95%) of inter day analysis were found to be in the range of 96.88 – 101.27, 
96.92 – 102.39, 95.20 – 105.19 and 99.69 – 100.38 for Metoprolol Tartrate, Ramipril, 
Atorvastatin Calcium and Aspirin, respectively. 
The accuracy of the method was confirmed by the recovery studies. To the      
pre-analyzed formulation, a known quantity of raw material was added and the 
percentage recovery was calculated. The percentage recovery was found to be in the 
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range of 99.00 - 99.99%, for Metoprolol Tartrate 99.86 - 101.26% for Ramipril,             
98.03 - 101.98 for Atorvastatin Calcium and 98.40 - 98.71 for Aspirin. The percentage 
RSD values were found to be 0.5087, 0.6978, 1.6383 and 0.1787 for Metoprolol Tartrate, 
Ramipril, Atorvastatin Calcium and Aspirin, respectively. The confidence interval (95%) 
for drugs was found to be in the range of 98.29 – 100.80, 98.84 – 102.33, 96.49 – 104.70 
and 98.16 – 99.03 for Metoprolol Tartrate, Ramipril, Atorvastatin Calcium and Aspirin, 
respectively. 
 Two instrumental analytical methods were successfully developed for the 
simultaneous estimation of Atorvastatin Calcium, Aspirin, Ramipril and           
Metoprolol Tartrate and in bulk and in pharmaceutical dosage form. 
The two methods were found to be accurate, precise and rapid for the 
simultaneous estimation of these drugs. This was confirmed by low percentage RSD 
values. The spectrophotometric method is found to be economical when compared to the 
HPTLC method. But HPTLC is more sensitive than UV spectrophotometric method. The 
low percentage RSD value in the recovery studies suggests that the excipients do not 
interfere in the analysis of formulation and hence all the methods are accurate. HPTLC is 
found to be more sensitive than other method. Because the linearity range, LOD, LOQ 
were less in HPTLC method than UV spectroscopic method. Hence it is suggested that 
these two methods can be applied successfully for the routine quality control analysis for 
the simultaneous estimation of Atorvastatin Calcium, Aspirin, Ramipril and     
Metoprolol Tartrate in bulk and in pharmaceutical dosage form and the obtained results 
will be presented elsewhere.      
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
IR SPECTRUM OF ATORVASTATIN CALCIUM
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Figure 2 
IR SPECTRUM OF ASPIRIN 
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Figure 3 
IR SPECTRUM OF RAMIPRIL 
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Figure 4 
IR SPECTRUM OF METOPROLOL TARTRATE
 
 
Figure 5 
OVERLAIN ZERO ORDER SPECTRA OF ATORVASTATIN CALCIUM, 
ASPIRIN, RAMIPRIL AND METOPROLOL TARTRATE 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 
OVERLAIN FIRST ORDER DERIVATIVE SPECTRUM OF ATORVASTATIN 
CALCIUM, ASPIRIN, RAMIPRIL AND METOPROLOL TARTRATE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 
CALIBRATION GRAPH OF ATORVASTATIN CALCIUM AT 291.5 nm 
(FIRST ORDER DERIVATIVE METHOD) 
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Figure 8 
CALIBRATION GRAPH OF ATORVASTATIN CALCIUM AT 247 nm 
(FIRST ORDER DERIVATIVE METHOD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 
CALIBRATION GRAPH OF ASPIRIN AT 247 nm 
(FIRST ORDER DERIVATIVE METHOD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 
CALIBRATION GRAPH OF ATORVASTATIN CALCIUM AT 242.5 nm 
(FIRST ORDER DERIVATIVE METHOD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 
CALIBRATION GRAPH OF ASPIRIN AT 242.5 nm 
(FIRST ORDER DERIVATIVE METHOD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 
CALIBRATION GRAPH OF RAMIPRIL AT 242.5 nm 
(FIRST ORDER DERIVATIVE METHOD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 
CALIBRATION GRAPH OF ATORVASTATIN CALCIUM AT 229.5 nm 
(FIRST ORDER DERIVATIVE METHOD) 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 14 
CALIBRATION GRAPH OF ASPIRIN AT 229.5 nm 
(FIRST ORDER DERIVATIVE METHOD) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15 
CALIBRATION GRAPH OF RAMIPRIL AT 229.5 nm 
(FIRST ORDER DERIVATIVE METHOD) 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 16 
CALIBRATION GRAPH OF METOPROLOL TARTRATE AT 229.5 nm 
 (FIRST ORDER DERIVATIVE METHOD)  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 17 
UV SPECTRUM OF METOPROLOL TARTRATE, RAMIPRIL, 
ATORVASTATIN CALCIUM AND ASPIRIN IN BENZENE: TOLUENE: 
METHANOL: GLACIAL ACETIC ACID (7.5:1.0:1.5:0.1 % V/V/V/V) 
(DETECTION WAVELENGTH) 
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Figure 18 
CHROMATOGRAM FOR METOPROLOL TARTRATE BY HPTLC 
(100 ng/ µl) 
 
Peak Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Max 
% 
End 
Rf 
End 
Height 
Area Area 
% 
 
 
1 
 
0.12 
 
3.4 
 
0.14 
 
46.3 
 
10.71 
 
0.18 
 
4.9 
 
237.1 
 
100 
 
 
 
  
 
 
Figure 19 
CHROMATOGRAM FOR RAMIPRIL BY HPTLC 
(10 ng/ µl) 
 
 
Peak Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Max 
% 
End 
Rf 
End 
Height 
Area Area 
% 
 
 
1 
 
0.22 
 
12.3 
 
0.26 
 
18.3 
 
4.64 
 
0.28 
 
10.5 
 
206.2 
 
100 
 
 
 
 
  
  
 
 
Figure 20 
CHROMATOGRAM FOR ATORVASTATIN CALCIUM BY HPTLC 
(20 ng/ µl) 
 
 
Peak Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Max 
% 
End 
Rf 
End 
Height 
Area Area 
% 
 
 
1 
 
0.36 
 
27.3 
 
0.40 
 
78.9 
 
18.21 
 
0.43 
 
16.9 
 
618.9 
 
100 
 
 
 
  
 
 
Figure 21 
CHROMATOGRAM FOR ASPIRIN BY HPTLC 
(75 ng/ µl) 
 
 
Peak Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Max 
% 
End 
Rf 
End 
Height 
Area Area 
% 
 
 
1 
 
0.96 
 
23.4 
 
0.99 
 
206.01 
 
45.6 
 
1.05 
 
35.3 
 
1304 
 
100 
 
 
  
 
 
Figure 22 
LINEARITY CHROMATOGRAM FOR METOPROLOL TARTRATE, 
RAMIPRIL, ATORVASTATIN CALCIUM AND ASPIRIN BY HPTLC 
(100+10+20+75 ng/ µl) 
 
Peak Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
height 
Max 
% 
End 
Rf 
End 
Height 
Area Area 
% 
 
1 
 
0.12   2.4 0.14 43.3   9.93 0.17   4.4  222.8   9.18 
2 
 
0.23 10.6 0.25 16.2   3.72 0.28 11.5  193.8   7.97 
3 
 
0.37 24.1 0.40 76.4 16.06 0.45 18.1  636.3 26.24 
4 0.94 22.3 0.99 19.71 42.28 1.03 37.5 1372.2 50.59 
 
  
 
 
Figure 23 
LINEARITY CHROMATOGRAM FOR METOPROLOL TARTRATE, 
RAMIPRIL, ATORVASTATIN CALCIUM AND ASPIRIN BY HPTLC 
(200+20+40+150 ng/ µl) 
 
Peak Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Max 
% 
End 
Rf 
End 
Rf 
Area Area 
% 
 
1 
 
0.13 2.7 0.14   43.0   6.02 0.16   5.5   456.2   9.41 
2 
 
0.24 10.7 0.25   21.3   5.58 0.29 15.0   387.3   8.03 
3 
 
0.37 20.4 0.40   70.3 18.43 0.45 19.6 1263.4 25.69 
4 0.94 21.6 0.99 188.8 49.49 1.04 37.8 2756.6 56.80 
 
  
 
 
Figure 24 
LINEARITY CHROMATOGRAM FOR METOPROLOL TARTRATE, 
RAMIPRIL, ATORVASTATIN CALCIUM AND ASPIRIN BY HPTLC 
(300+30+60+225 ng/ µl) 
 
Peak Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Max 
% 
End 
Rf 
End 
Height 
Area Area 
% 
 
1 
 
0.11 3.3 0.14  44.3 12.36 0.17  6.8  664.2  9.10 
2 
 
0.23 13.1 0.25  27.4   7.63 0.27 18.9  589.2  8.07 
3 
 
0.36 22.6 0.40  98.1 27.37 0.47 12.2 1927.5 25.42 
4 
 
0.94 24.3 0.99 208.9 54.88 1.04 39.4 4112.4 56.38 
 
  
 
 
Figure 25 
LINEARITY CHROMATOGRAM FOR METOPROLOL TARTRATE, 
RAMIPRIL, ATORVASTATIN CALCIUM AND ASPIRIN BY HPTLC 
(400+40+80+300 ng/ µl) 
 
Peak Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Max 
% 
End 
Rf 
End 
Height 
Area Area 
% 
 
1 
 
0.12   2.3 0.14  60.6 16.84 0.16 3.9  889.2  9.18 
2 
 
0.22 11.5 0.25  33.6  9.35 0.27 19.5  773.8  8.05 
3 
 
0.36 21.4 0.40 124.5 34.62 0.46 12.1 2598.5 26.18 
4 0.94 26.2 0.99 219.2 59.19 1.05 41.3 5483.7 56.57 
 
  
 
 
Figure 26 
LINEARITY CHROMATOGRAM FOR METOPROLOL TARTRATE, 
RAMIPRIL, ATORVASTATIN CALCIUM AND ASPIRIN BY HPTLC 
(500+50+100+375 ng/ µl) 
 
 
Peak Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Max 
% 
End 
Rf 
End 
Height 
Area Area 
% 
 
1 
 
0.12  2.7 0.14  76.1 29.41 0.16  2.1 1121.4  9.05 
2 
 
0.22  6.8 0.25  36.0 13.91 0.27 15.1  960.4  7.90 
3 
 
0.35 17.6 0.40 146.6 56.68 0.45 13.4 3151.4 26.76 
4 0.94 27.9 0.99 232.0 62.12 1.05 41.9 6859.2 56.27 
 
  
 
 
Figure 27 
LINEARITY CHROMATOGRAM FOR METOPROLOL TARTRATE, 
RAMIPRIL, ATORVASTATIN CALCIUM AND ASPIRIN BY HPTLC 
(600+60+120+450 ng/ µl) 
 
Peak Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Max 
% 
End 
Rf 
End 
Height 
Area Area 
% 
 
1 
 
0.11  1.6 0.14  91.6 25.61 0.17  0.5 1338.2  9.02 
2 
 
0.22  6.6 0.25  44.3 12.40 0.26 15.1 1134.3  7.82 
3 
 
0.36 18.8 0.40 170.1 47.57 0.45 17.0 3816.3 26.92 
4 0.94 28.2 0.99 241.2 63.13 1.06 42.5 8430.2 56.23 
 
  
 
 
Figure 28 
CALIBRATION GRAPH FOR METOPROLOL TARTRATE BY HPTLC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29 
CALIBRATION GRAPH FOR RAMIPRIL BY HPTLC 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 30 
CALIBRATION GRAPH FOR ATORVASTATIN CALCIUM BY HPTLC 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 31 
CALIBRATION GRAPH FOR ASPIRIN BY HPTLC METHOD 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 32 
CHROMATAGRAM FOR FORMULATION ANALYSIS BY HPTLC  
REPEATABILITY 1 
 
Peak Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Max 
% 
End 
Rf 
End 
Height  
Area Area 
% 
 
1 
 
0.12  7.8 0.15  16.9  3.23 0.17 12.3  221.9  9.40 
2 
 
0.23 15.7 0.25  27.4  5.25 0.27 13.6  195.3  7.88 
3 
 
0.37 27.8 0.40  88.7 16.54 0.43 21.6  632.6 26.02 
4 0.94 24.6 0.99 205.2 54.82 1.04 39.4 2752.6 56.68 
 
  
 
 
Figure 33 
CHROMATOGRAM FOR FORMULATION ANALYSIS BY HPTLC 
REPEATABLITY 2 
 
Peak Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Max 
% 
End 
Rf 
End 
Height 
Area Area 
% 
 
1 
 
0.12  7.6 0.15  16.7  3.29 0.17 12.3  223.5  9.34 
2 
 
0.23 15.6 0.25  27.5  5.25 0.27 13.4  197.3  7.96 
3 
 
0.37 27.4 0.40  88.5 16.40 0.43 21.2  631.4 26.09 
4 0.95 23.9 0.99 204.6 55.85 1.05 39.8 2756.7 56.59 
 
  
 
 
Figure 34 
CHROMATOGRAM FOR FORMULATION ANALYSIS BY HPTLC 
REPEATABILITY 3 
 
Peak Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Max 
% 
End 
Rf 
End 
Height 
Area Area 
% 
 
1 0.13  8.8 0.15  21.3  4.57 0.18 12.8  225.2  9.22 
 
2 0.23 14.3 0.25  25.1  5.39 0.27 19.3  198.1  7.92 
 
3 0.38 24.9 0.40  95.2 20.43 0.43 18.2  634.6 25.70 
 
4 0.95 25.8 0.99 209.7 52.73 1.04 39.7 2755.3 57.19 
 
  
 
 
Figure 35 
CHROMATOGRAM FOR FORMULATION ANALYSIS BY HPTLC 
REPEATABILITY 4 
 
Peak Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Max 
% 
End 
Rf 
End 
Height 
Area Area 
% 
 
1 0.14  8.1 0.15  18.6  4.18 0.19  9.6  224.6  9.26 
 
2 0.22 14.4 0.25  24.6  5.36 0.27 20.9  196.4  7.96 
 
3 0.37 23.9 0.40  95.2 23.57 0.44 18.5  640.2 25.64 
 
4 0.95 25.1 0.99 211.3 53.89 1.06 39.9 2759.7 57.11 
 
  
 
 
Figure 36 
CHROMATOGRAM FOR FORMULATION ANALYSIS BY HPTLC 
REPEATABILITY 5 
 
Peak Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
height 
Max 
% 
End 
Rf 
End 
Height 
Area Area 
% 
 
1 0.14  7.8 0.14  16.1  3.75 0.16 10.5  226.2  9.49 
 
2 0.22 14.5 0.25  26.4  5.81 0.27 20.5  196.2  8.06 
 
3 0.39 23.1 0.40  85.0 24.28 0.43 19.3  633.9 25.77 
 
4 0.95 25.6 0.99 215.0 53.15 1.06 39.8 2754.8 56.66 
 
  
 
 
Figure 37 
CHROMATOGRAM FOR FORMULATION ANALYSIS BY HPTLC 
REPEATABILITY 6 
 
Peak Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Max 
% 
End 
Rf 
End 
Height 
Area Area 
% 
 
1 0.14  8.5 0.14  18.9  4.24 0.16 12.3  227.1  9.54 
 
2 0.23 14.9 0.25  24.7  6.63 0.26 20.9  198.2  7.95 
 
3 0.37 23.9 0.40  92.8 25.82 0.42 19.9  641.5 25.98 
 
4 0.96 24.8 0.99 219.3 53.64 1.05 37.6 2758.6 56.03 
 
  
 
 
Figure 38 
CHROMATOGRAM FOR THE RECOVERY ANALYSIS OF FORMULATION  
RECOVERY 1 
 
Peak Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Max 
% 
End 
Rf 
End 
Height 
Area Area 
% 
 
1 0.12 13.7 0.15  53.3  8.66 0.18 15.5  402.8  9.47 
 
2 0.24 22.7 0.26  36.6  7.11 0.28 25.5  353.2  8.02 
 
3 0.39 32.7 0.41 122.6 40.44 0.43 31.3 1152.1 25.71 
 
4 0.95 42.9 0.99 393.1 61.44 1.04 68.9 4956.2 56.78 
 
  
 
 
Figure 39 
CHROMATOGRAM FOR THE RECOVERY ANALYSIS OF FORMULATION 
RECOVERY 2 
 
Peak Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Max 
% 
End 
Rf 
End 
Height 
Area Area 
% 
 
1 0.13 11.9 0.15  57.0   8.52 0.18 15.8  446.4  9.43 
 
2 0.23 22.1 0.25  34.3   5.13 0.28 23.7  393.2  7.96  
 
3 0.38 32.4 0.40 126.2 18.87 0.45 30.8 1281.9 25.74 
 
4 0.94 49.9 0.99 400.1 59.65 1.02 72.8 5507.3 56.86 
 
  
 
 
Figure 40 
CHROMATOGRAM FOR THE RECOVERY ANALYSIS OF FORMULATION 
RECOVERY 3 
 
Peak Start 
Rf 
Start 
Height 
Max 
Rf 
Max 
Height 
Max 
% 
End 
Rf 
End 
Height 
Area Area 
% 
 
1 0.13 18.8 0.15  15.3  2.01 0.17 10.7  492.5  9.45 
 
2 0.23 25.8 0.25  39.1  5.15 0.28 28.7  432.6  8.07 
 
3 0.37 34.8 0.40 130.2 17.15 0.44 33.8 1411.3 25.58 
 
4 0.97 17.4 0.99 418.7 54.92 1.03 94.2 6059.4 56.89 
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Table 1 
SOLUBILITY PROFILE OF ATORVASTATIN CALCIUM 
S.NO        SOLVENT EXTENT OF 
SOLUBILTY 
CATEGORY 
1. Distilled water  More than 100 ml Practically insoluble 
2. Methanol 10 mg in 0.1 ml Freely soluble 
3. Ethanol 10 mg in 0.3 ml soluble 
4. Acetonitrile 10 mg in 0.3 ml Soluble 
5. Dimethylformamide 10 mg in 3 ml Slightly soluble 
6. Acetone 10 mg in 0.5 ml Sparingly soluble 
7. Acetic Acid More than 100 ml Practically insoluble 
8. Ethyl Acetate 10 mg in 20 ml Very slightly soluble 
9. Chloroform 10 mg in 20 ml Very slightly soluble 
10. n-Butanol More than 100 ml Practically insoluble 
11. Benzene More than 100 ml Practically insoluble 
12. Toluene More than 100 ml Practically insoluble 
13. Isopropyl alcohol More than 100 ml Practically insoluble 
14. Hexane 10 mg in 6 ml Slightly soluble 
15. 0.1 M Hydrochloric acid More than 100 ml Practically insoluble 
16. 0.1 M Sodium hydroxide More than 100 ml Practically insoluble 
17. Dichloromethane 10 mg in 1 ml Sparingly soluble 
18. Diethyl ether More than 100 ml Practically insoluble 
19. Acid phthalate buffer(pH3) More than 100 ml Practically insoluble 
20. Neutralized  buffer (pH5) More than 100 ml Practically insoluble 
21. Phosphate buffer (pH7) More than 100 ml Practically insoluble 
22. Alkaline buffer (pH8) 10 mg in 10 ml  Slightly soluble 
` 
 
 
 
 
Table 2 
SOLUBILITY PROFILE OF ASPIRIN 
S.NO        SOLVENT EXTENT OF 
SOLUBILTY 
CATEGORY 
1. Distilled water 10 mg in 11 ml  Very slightly soluble 
2. Methanol 10 mg in 50 µl  Freely soluble 
3. Ethanol 10 mg in 70 µl Freely soluble 
4. Acetonitrile 10 mg in 70 µl  Freely soluble 
5. Dimethylformamide  10 mg  in 50 µl   Freely soluble 
6. Acetone 10 mg in 0.5 ml Sparingly soluble 
7. Acetic Acid 10 mg in 1.5 ml Slightly soluble 
8. Ethyl Acetate 10 mg in 0.2 ml Soluble 
9. Chloroform 10 mg in 0.3 ml Soluble 
10. n-Butanol 10 mg in 0.5 ml Sparingly soluble 
11. Benzene 10 mg in 1.1 ml Slightly soluble 
12. Toluene 10 mg in 5 ml Slightly soluble 
13. Isopropyl alcohol 10 mg in 50 µl  Freely soluble 
14. Hexane 10 mg in 2 ml Slightly soluble 
15. 0.1 M Hydrochloric acid 10 mg in 5 ml Slightly soluble 
16. 0.1 M Sodium hydroxide 10 mg in 0.5 ml Sparingly soluble 
17. Dichloromethane 10 mg in 0.2 ml Soluble 
18. Diethyl ether 10 mg in 0.5 ml Sparingly soluble 
19. Acid phthalate buffer pH3 10 mg in 5.1 ml Slightly soluble 
20. Neutralized buffer (pH5) 10 mg in 4.1 ml Slightly soluble 
21. Phosphate buffer (pH7) 10 mg in 1 ml Sparingly soluble 
22. Alkaline buffer (pH9) 10 mg in 0.5 ml Sparingly soluble 
 
 
 
 
 
Table 3 
SOLUBILITY PROFILE OF RAMIPRIL 
 
 
 
S.NO        SOLVENT EXTENT OF 
SOLUBILTY 
CATEGORY 
1. Distilled water 10 mg in 10 ml Very slightly soluble  
2. Methanol 10mg in 70 µl Freely soluble 
3. Ethanol 10 mg in 80 µl Freely soluble 
4. Acetonitrile 10 mg in 70 µl Freely soluble 
5. Dimethylformamide 10 mg in 1.5 ml Slightly soluble 
6. Acetone 10 mg in 0.1 ml Soluble 
7. Acetic Acid 10 mg in 50 µl Freely soluble 
8. Ethyl Acetate 10 mg in 9 ml Slightly soluble 
9. Chloroform 10 mg in 30 µl Freely soluble 
10. n-Butanol More than 100 ml Practically insoluble 
11. Benzene 10 mg in 1.5 ml Slightly soluble 
12. Toluene 10 mg in 0.1 ml Soluble 
13. Isopropyl alcohol 10 mg in 0.6 ml Sparingly soluble 
14. Hexane More than 100 ml  Practically inSoluble 
15. 0.1 M Hydrochloric acid 10 mg in 0.5 ml Sparingly soluble 
16. 0.1 M Sodium hydroxide 10 mg in 0.9 ml Practically insoluble 
17. Dichloromethane 10 mg in 30 µl Freely soluble 
18. Diethyl ether 10 mg in 5 ml Slightly soluble 
19. Acid phthalate buffer pH3 10 mg in 1.5 ml Slightly soluble 
20. Neutralized buffer (pH5) More than 100 ml Practically insoluble 
21. Phosphate buffer (pH7) 10 mg in 10 ml Slightly soluble 
22. Alkaline buffer (pH9) 10 mg in 5 ml Slightly soluble 
 
 
Table 4 
SOLUBILITY PROFILE OF METOPROLOL TARTRATE 
S.NO        SOLVENT EXTENT OF 
SOLUBILTY 
CATEGORY 
1. Distilled water 10 mg in 10 µl  Very soluble 
2. Methanol 10 mg in 10 µl Very soluble 
3. Ethanol 10 mg in 40 µl Freely soluble 
4. Acetonitrile 10 mg in 0.4 ml Sparingly soluble 
5. Dimethylformamide 10 mg in 0.6 ml Sparingly soluble 
6. Acetone 10 mg in 1.3 ml Slightly soluble 
7. Acetic Acid 10 mg in 1 ml Sparingly soluble 
8. Ethyl Acetate 10 mg in 0.3ml Soluble 
9. Chloroform 10 mg in 0.6ml Sparingly soluble 
10. n-Butanol 10 mg in 0.5 ml Sparingly soluble 
11. Benzene 10 mg in 0.2 ml Soluble 
12. Toluene 10 mg in 2 ml Slightly soluble 
13. Isopropyl alcohol 10 mg in 70 µl Freely soluble 
14. Hexane 10 mg in 0.2 ml Soluble 
15. 0.1 M Hydrochloric acid 10 mg in 0.5 ml Sparingly soluble 
16. 0.1 M Sodium hydroxide 10 mg in1.5 ml Slightly soluble 
17. Dichloromethane 10 mg in 2 ml Slightly soluble 
18. Diethyl ether 10 mg in 0.6 ml Sparingly soluble 
19. Acid phthalate buffer pH3 10 mg in 0.2 ml Soluble 
20. Neutralized buffer (pH5) 10 mg in 50 µl Freely soluble 
21. Phosphate buffer (pH7) 10 mg in 100 l Freely soluble 
22. Alkaline buffer (pH9) 10 mg in 100 µl Freely soluble 
 
   
  
 
 
Table 5 
OPTICAL CHARACTERISTICS OF ATORVASTATIN CALCIUM 
(FIRST ORDER DERIVATIVE SPECTROPHOTOMETRY) μg/ml 
PARAMETERS AT 291.5 nm* 
Beers law limit  (μg/ ml) 3 - 21 
Molar absorptivity (L mol-1cm-1) 740.67 
Sandell’s sensitivity (μg/cm2/0.001 A.U) 1.5960 
Correlation coefficient (r) 0.9999 
Regression equation (Y=mx+c) Y = 0.0006x +(-) 0.0001 
Slope (m) 0.0006 
Intercept (c) (-) 0.0001 
LOD (μg/ ml) 0.6176 
LOQ (μg/ ml) 1.8714 
Standard Error 0.00003 
(*Mean of six observations) 
 
 
 
 
          
 
 
 Table 6 
OPTICAL CHARACTERISTICS OF ASPIRIN 
(FIRST ORDER DERIVATIVE SPECTROPHOTOMETRY) 
PARAMETERS AT 247 nm* 
Beers law limit  (μg/ ml) 10 - 70 
Molar absorptivity (L mol-1cm-1) 117.52 
Sandell’s sensitivity (μg/cm2/0.001 A.U) 1.0017 
Correlation coefficient (r) 0.9968 
Regression equation (Y=mx+c) Y = 0.0009x+ (-) 0.0035 
Slope (m) 0.0009 
Intercept (c) (-) 0.0035 
LOD (μg/ ml) 0.1432 
LOQ (μg/ ml) 0.4343 
Standard Error 0.00002 
(*Mean of six observations) 
 
 
 
 
  
 
 
Table 7 
OPTICAL CHARACTERISTICS OF RAMIPRIL 
(FIRST ORDER DERIVATIVE SPECTROPHOTOMETRY) 
PARAMETERS AT 242.5 nm* 
Beers law limit  (μg/ ml) 10 - 70 
Molar absorptivity (L mol-1cm-1) 66.66 
Sandell’s sensitivity (μg/cm2/0.001 A.U) 6.1907 
Correlation coefficient (r) 0.9996 
Regression equation (Y=mx+c) Y = 0.0002x+ (-) 0.0001 
Slope (m) 0.0002 
Intercept (c) (-) 0.0001 
LOD (μg/ ml) 1.6587 
LOQ (μg/ ml) 5.0263 
Standard Error 0.00002 
(*Mean of six observations) 
 
 
 
 
  
 
 
Table 8 
OPTICAL CHARACTERISTICS OF METOPROLOL TARTRATE 
(FIRST ORDER DERIVATIVE SPECTROPHOTOMETRY) 
PARAMETERS AT 229.5 nm* 
Beers law limit  (μg/ ml) 10 - 70 
Molar absorptivity (L mol-1cm-1) 672.118 
Sandell’s sensitivity (μg/cm2/0.001 A.U) 0.3742 
Correlation coefficient (r) 0.9998 
Regression equation (Y=mx+c) Y = 0.0027x+ (-) 0.0016 
Slope (m) 0.0027 
Intercept (c) (-) 0.0016 
LOD (μg/ ml) 0.1310 
LOQ (μg/ ml) 0.3969 
Standard Error 0.00003 
(*Mean of six observations) 
 
 
 
 
  
 
 
Table 9 
ANALYSIS OF SYNTHETIC MIXTURE 
Drug 
Concentration 
prepared    
(µg/ ml) 
Amount 
Found           
(µg/ ml)* 
Percentage 
Purity* 
Average 
(%) SD RSD SE 
ATR 
4 
8 
12 
16 
20 
3.92 
8.07 
12.06 
15.89 
20.04 
98.00 
100.87 
100.50 
99.31 
100.20 
99.78 1.1481 1.1506 0.0459 
ASP 
30 
40 
50 
60 
70 
30.11 
39.60 
49.30 
58.90 
69.74 
100.36 
99.00 
98.60 
98.16 
99.62 
99.15 0.8646 0.8720 0.0346 
RAM 
30 
40 
50 
60 
70 
30.16 
39.77 
50.42 
60.20 
69.46 
100.53 
99. 42 
100.84 
100.33 
99.22 
100.07 0.7101 0.7096 0.0284 
MET 
30 
40 
50 
60 
70 
30.07 
40.37 
50.43 
60.73 
70.24 
100.23 
100.92 
100.86 
101.21 
100.34 
100.71 0.4135 0.4106 0.0165 
(* Mean of six observations) 
 
 
Table 10 
QUANTIFICATION OF FORMULATION (ZYCAD-4) 
Drug 
Label 
Claim  
(mg/tab) 
Amount 
Found 
(mg/tab)* 
Percentage 
Obtained* 
Average 
(%) SD RSD SE 
ATR 
10 
10 
10 
10 
10 
10 
10.1849 
10.1747 
10.4575 
10.4692 
10.1911 
10.1826 
101.84 
101.74 
104.57 
104.69 
101.91 
101.82 
102.76 1.4487 1.4097 0.0402 
ASP 
75 
75 
75 
75 
75 
75 
73.9410 
72.3707 
74.2635 
75.8524 
73.9855 
75.1467 
98.58 
96.49 
99.01 
101.11 
98.64 
100.19 
99.00 1.5795 1.5954 0.0438 
RAM 
5 
5 
5 
5 
5 
5 
5.0974 
4.9926 
4.9648 
4.8815 
5.1005 
4.9515 
101.94 
99.85 
99.29 
97.63 
102.01 
99.03 
99.95 1.7250 1.7257 0.0479 
MET 
50 
50 
50 
50 
50 
50 
49.2274 
49.0784 
49.0568 
49.0374 
49.4569 
50.1394 
98.45 
98.15 
98.11 
98.07 
98.91 
100.27 
98.66 0.8496 0.8612 0.0236 
(*Mean of six observations) 
  
 
 
Table 11 
INTRADAY AND INTER DAY ANALYSIS OF FORMULATION (ZYCAD-4) 
Drug 
Amount   
labeled 
(mg/tab) 
Percentage 
Obtained* SD %RSD 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
ATR 
10 
10 
10 
102.02 
101.71 
101.89 
101.82 
101.94 
101.94 
 
0.1557 
 
0.0693 
 
0.1528 
 
0.0680 
Mean 101.87 101.90  
ASP 
75 
75 
75 
98.75 
100.08 
98.63 
98.99 
99.55 
99.51 
0.8048 0.3124 0.8116 0.3145 
Mean 99.15 99.35  
RAM 
5 
5 
5 
101.61 
102.26 
98.65 
102.52 
100.38 
100.61 
1.9222 1.1748 1.9063 1.1612 
Mean 100.84 101.17  
MET 
50 
50 
50 
98.62 
98.42 
101.48 
98.58 
99.98 
97.95 
1.7119 1.0391 1.7204 1.0513 
Mean 99.51 98.83  
(*Mean of six observations) 
 
  
 
 
Table 12 
RUGGEDNESS STUDY 
Drug Condition Percentage Obtained SD %RSD SE 
 
 
ATR 
 
Analyst 1 102.73 1.4218 1.3842 0.0394 
Analyst 2 101.94 0.2943 0.2887 0.0081 
Instrument 1 102.05 0.1635 0.1602 0.0045 
Instrument 2 99.96 1.5147 1.5153 0.0420 
 
ASP 
 
 
Analyst 1 99.00 1.5795 1.5954 0.0438 
Analyst 2 99.53 1.8311 1.8396 0.0509 
Instrument 1 99.40 0.6644 0.6684 0.0184 
Instrument 2 99.01 0.4419 0.4463 0.0128 
RAM 
Analyst 1 99.95 1.7249 1.7256 0.4791 
Analyst 2 99.99 1.8625 1.8602 0.0517 
Instrument 1 101.11 2.0040 1.9820 0.0557 
Instrument 2 99.80 1.0762 1.0783  0.0299 
MET 
Analyst 1 98.66 0.8496 0.8611 0.0236 
Analyst 2 99.07 0.8289 0.8367 0.0230 
Instrument 1 98.97 1.2756 1.2887 0.0354 
Instrument 2 99.03 0.8143 0.8223 0.0226 
 
 
 
 
 
Table 13 
RECOVERY ANALYSIS OF FORMULATION (ZYCAD-4) 
Drug 
Amount 
Present 
(µg/tab) 
Amount 
Added 
(µg/tab)* 
Amount 
Estimated 
(µg/tab)* 
Amount 
Recovered 
(µg/tab)* 
Percentage 
Recovered* SD %RSD SE 
ATR 
4.1333 
4.1333 
4.1333 
 
2.4799 
3.7199 
4.9599 
6.6244 
7.8615 
9.0816 
2.4911 
3.7282 
4.9483 
100.45 
100.22 
99.76 
 
0.3513 
 
0.3508 
 
0.0390 
Mean 100.40 
ASP 
29.8667 
29.8667 
29.8667 
23.8933 
29.8667 
35.8400 
53.8515 
60.0584 
65.9412 
23.9848 
30.1917 
36.0745 
100.38 
101.08 
100.65 
 
0.3530 
 
0.3506 
 
0.0392 
Mean 100.70 
RAM 
20.1010 
20.1010 
20.1010 
12.0606 
18.0909 
24.1212 
31.9905 
38.4895 
44.3816 
11.8895 
18.3885 
24.2806 
98.58 
101.64 
100.66 
 
1.5626 
 
1.5580 
 
0.1736 
Mean 100.29 
MET 
19.8492 
19.8492 
19.8492 
11.9095 
17.8642 
23.8190 
31.5875 
37.4166 
44.0712 
11.7383 
17.5674 
24.2220 
98.56 
98.33 
101.69 
 
 
1.8770 
 
1.8860 
 
0.2086 
Mean 99.52 
(* Mean of three observations)
 
 
Table 14 
OPTICAL CHARACTERISTICS OF METOPROLOL TARTRATE 
(HPTLC METHOD) 
PARAMETERS METOPROLOL  TARTRATE 
Detection Wavelength 224 nm 
Beers law limit  (ng/ μl) 100 - 600 
Correlation coefficient (r) 0.9999 
Regression equation (Y=mx+c) Y = 2.2297x+ 0.9164 
Slope (m) 2.2297 
Intercept (c) 0.9167 
LOD (ng/ μl) 0.7632 
LOQ (ng/ μl) 2.3128 
Standard Error 0.4449 
(*Mean of three observations) 
 
 
 
 
 
 
 
 
Table 15 
OPTICAL CHARACTERISTICS OF RAMIPRIL 
(HPTLC METHOD) 
PARAMETERS RAMIPRIL* 
Detection Wavelength 224 nm 
Beers law limit  (ng/ μl) 10 - 60 
Correlation coefficient (r) 0.9998 
Regression equation (Y=mx+c) Y = 19.043x+ 6.272 
Slope (m) 19.043 
Intercept (c) 6.272 
LOD (ng/ μl) 0.1025 
LOQ (ng/ μl) 0.3105 
Standard Error 0.1427 
(Mean of three observations) 
 
 
 
 
 
 
 
 
Table 16 
OPTICAL CHARACTERISTICS OF ATORVASTATIN CALCIUM 
(HPTLC METHOD) 
PARAMETERS ATORVASTATIN CALCIUM* 
Detection Wavelength 224 nm 
Beers law limit  (ng/ μl) 20 to 120 
Correlation coefficient (r) 0.9998 
Regression equation (Y=mx+c) Y = 31.775x+ 5.6914 
Slope (m) 31.7751 
Intercept (c) 5.6917 
LOD (ng/ μl) 0.1272 
LOQ (ng/ μl) 0.3855 
Standard Error 0.1471 
(*Mean of three observations) 
 
 
 
 
 
 
 
 
Table 17 
OPTICAL CHARACTERISTICS OF ASPIRIN 
(HPTLC METHOD) 
PARAMETERS ASPIRIN* 
Detection Wavelength 224 nm 
Beers law limit  (ng/ μl) 75 to 450 
Correlation coefficient (r) 0.9998 
Regression equation (Y=mx+c) Y = 18.561x+ (-)30.8631 
Slope (m) 18.5616 
Intercept (c) (-) 30.8631 
LOD (ng/ μl) 0.2955 
LOQ (ng/ μl) 0.8954 
Standard Error 0.0821 
(*Mean of three observations) 
 
 
 
 
 
 
 
 
Table 18 
QUANTIFICATION OF FORMULATION (ZYCAD-4) BY HPTLC 
Drug 
Label 
Claim 
(mg/tab) 
Amount 
Found 
(mg/tab)* 
Percentage 
Obtained 
Average 
(%)* SD RSD SE 
 
MET 
50 
50 
50 
50 
50 
50 
49.4905 
49.8501 
50.2296 
50.0948 
50.4543 
50.6541 
98.98 
99.70 
100.45 
100.90 
100.90 
101.30 
100.24 0.8348 0.8328 0.0232 
RAM 
5 
5 
5 
5 
5 
5 
4.9540 
5.0089 
5.0289 
4.9840 
4.9790 
5.0289 
99.08 
100.07 
100.57 
99.68 
99.58 
100.57 
99.93 0.5910 0.5914 0.0164 
ATR 
10 
10 
10 
10 
10 
10 
9.8481 
9.8331 
9.8831 
9.9680 
9.8731 
9.9929 
98.48 
98.33 
98.83 
99.68 
98.73 
99.92 
99.00 0.6526 0.6593 0.0181 
ASP 
75 
75 
75 
75 
75 
75 
74.8950 
74.9948 
74.9599 
75.0797 
74.9449 
75.0498 
99.86 
99.99 
99.94 
100.10 
99.92 
100.01 
99.97 0.0829 0.0830 0.0023 
(*Mean of six observations) 
 
 
Table 19 
INTRADAY AND INTER DAY ANALYSIS OF FORMULATION (ZYCAD-4) 
(HPTLC) 
 
Drug 
Amount   
Labeled 
(mg/ tab) 
Percentage 
Obtained* 
SD %RSD 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
Intra 
day 
Inter 
day 
MET 
50 
50 
50 
99.24 
100.14 
100.76 
101.16 
98.66 
100.42 
 
0.7643 
 
1.2842 
 
0.7639 
 
1.2832 
Mean 100.04 100.08  
RAM 
5 
5 
5 
100.80 
100.40 
99.40 
100.80 
98.60 
99.60 
0.7211 1.1015 0.7197 1.1052 
Mean 100.20 99.66  
ATR 
10 
10 
10 
98.90 
98.70 
98.60 
102.70 
98.50 
99.40 
0.1527 2.0113 0.1547 2.0167 
Mean 98.73 100.20  
ASP 
75 
75 
75 
99.96 
99.93 
100.04 
100.18 
99.90 
100.04 
0.3150 0.1400 0.3158 0.1399 
Mean 99.76 100.04  
(*Mean of six observations) 
 
 
Table 20 
RECOVERY ANALYSIS OF FORMULATION (ZYCAD-4) BY HPTLC 
Drug 
Amount 
Present 
(µg/ ml) 
Amount 
Added  
(µg/ ml)* 
Amount 
Estimated 
(µg/ ml)* 
Amount 
Recovered 
(µg/ ml)* 
Percentage 
Recovered* SD %RSD SE 
 
MET 
100.3783 
100.3783 
100.3783 
 
 80.3026 
100.3786 
120.4539 
180.6733 
199.7600 
220.4533 
 80.2950 
 99.3817 
120.0750 
 99.99 
 99.00 
 99.68 
 
0.5064 
 
0.5087 
 
0.0563 
Mean  99.55 
 
RAM 
10.0066 
10.0066 
10.0066 
 8.0052 
10.0066 
12.0079 
18.1100 
20.0000 
22.0933 
 8.1034 
 9.9934 
12.0867 
101.26 
 99.86 
100.65 
 
0.7019 
 
0.6978 
 
0.0780 
Mean 100.59 
 
ATR 
19.8233 
19.8233 
19.8233 
15.8586 
19.8233 
23.7879 
35.5285 
40.0052 
44.2833 
15.7052 
20.1819 
24.2600 
 98.03 
101.80 
101.98 
 
1.6536 
 
1.6383 
 
0.1837 
Mean 100.60 
 
ASP 
150.1550 
150.1550 
150.1550 
120.4400 
150.1550 
180.1860 
268.8700 
298.3766 
328.0066 
118.5150 
148.2216 
177.8516 
 98.40 
 98.71 
 98.70 
 
 
0.1762 
 
0.1787 
 
0.0196 
Mean  98.60 
(* Mean of three observations)
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